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ABSTRACT 
          Mitochondrial dysfunction in skeletal muscle has been considered as a crucial step 
in the development of metabolic diseases, including insulin resistance syndrome, type 2 
diabetes and cardiovascular diseases. Previous studies have demonstrated that dietary 
branched-chain amino acids, particularly leucine, protects against high-fat diet induced 
impairment of mitochondria and insulin resistance in skeletal muscle and adipose tissue 
through mTOR-dependent and independent pathways. In addition, previous ex vivo and 
in vitro approaches from this laboratory indicate that leucine and its metabolites (HMB 
and KIC) stimulate mitochondrial biogenesis and promote energy partitioning from 
adipocytes to muscle cells, partially through SIRT1 signaling. Moreover, recent work 
indicates that HMB promotes AMPK phosphorylation synergistically with metformin, 
resulting in increased insulin sensitivity and glucose tolerance in HFD mice. Therefore, it 
is hypothesized that leucine-induced activation of SIRT1 and AMPK are the central 
events that link to the up-regulated mitochondrial biogenesis and fatty acid oxidation in 
skeletal muscle. Thus, SIRT1 activity, AMPK phosphorylation level, fatty acid oxidation, 
mitochondrial content and mitochondrial biogenesis related genes expressions were 
measured in C2C12 myotubes after incubated with leucine and controls. Furthermore, 
considering SIRT1 and AMPK share multiple downstream substrates and display mutual 
interactions in response to energy restriction, C2C12 myotubes were treated with SIRT1 
inhibitor, EX527, and AMPK inhibitor, Compound C, to determine the respective roles of 
SIRT1 and AMPK in leucine effects on mitochondrial biogenesis. Additionally, a time-
course experiment was conduced to elucidate the relationship between SIRT1 and 
AMPK. The results of this research confirm that leucine increased mitochondrial 
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biogenesis and fatty acid oxidation in C2C12 myotubes via SIRT1 and AMPK dependent 
pathways, with SIRT1 activation being the primary event.  
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          According to the WHO (World Health Organization), over 1 billion adults are 
overweight or obese (BMI (Body Mass Index, Kg/m2) >25 kg/m2 defined as overweight; 
>30 kg/m2 as obese) worldwide [1], and this global obesity prevalence has been increased 
rapidly for the last three decades. In the United States, by the year 2013, 154.7 million 
(63.1% of total) were overweight or obese among Americans age 20 and older [2]. This 
rapidly increasing prevalence of obesity has tremendous impacts on individual health and 
society. For example, obesity is highly associated with increased risk of chronic diseases, 
including type 2 diabetes, cancers, and cardiovascular diseases [3]. The American Heart 
Association estimates that by 2030, total healthcare costs caused by obesity could reach 
$861 to $957 billion in US, which would be 20% of the total health expenditures [5]. 
Therefore, obesity has become a critical area in medical sciences, with the goals to 
understand mechanisms of obesity-related pathological development, and to discover 
pharmacological molecules to inhibit these effects. 
          Mitochondrial dysfunction includes decreased mitochondrial content, lower 
expression levels of oxidative enzymes, and decreased ATP synthesis rate [7]. 
Mitochondrial dysfunction and the related accumulation of lipid intermediates have been 
demonstrated to contribute to the pathogenesis of obese-related diseases and aging [4], 
and there have been extensive studies focusing on promoting mitochondrial biogenesis 
and lipid oxidation in skeletal muscle and understanding the fundamental cellular 
molecular mechanisms [8-10].  
          During the past decade, the view of skeletal muscle has changed from a contractile 
apparatus to that of an active secretory organ that produces and releases multiple 
hormones and myokines, such as myostatin, osteogenic factors IGF-1 and irisin [4, 5]. In 
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addition, skeletal muscle is a major site for insulin action to maintain whole body energy 
homeostasis [6].  
          Branched-chain amino acids (leucine, isoleucine and valine) have been shown to 
display beneficial effects against metabolic diseases [11]. In addition to promote protein 
synthesis, leucine has been demonstrated to increase mitochondrial oxidative function 
and restore insulin sensitivity in skeletal muscle through both mammalian target of 
rapamycin (mTOR)-dependent and independent pathways [12]. Recent studies have 
shown that SIRT1, a NAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase, 
and AMP-activated protein kinase (AMPK) might also contribute to the leucine effects 
on energy metabolism [13, 14]. 
 Therefore, considering the evidence of leucine modulation on energy metabolism 
and the activation SIRT1 and AMPK signaling pathways in skeletal muscle, the 
objectives of this project are: 1) to confirm the roles of leucine in mitochondrial 
biogenesis and fatty acid oxidation; and 2) to elucidate the roles of SIRT1 and AMPK in 
leucine regulation of mitochondrial biogenesis in C2C12 myotubes. 
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Figure 1-1 The hypothetical leucine activating SIRT1-AMPK cycle. 
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2.1    The role of mitochondria in energy metabolism 
2.1.1    Mitochondrial functions and mitochondrial biogenesis 
           Mitochondria, as one of the most important double membrane-bound organelles in 
cells, play essential roles in energy metabolism, cell signaling and apoptosis [15]. The 
double-membrane structure in mitochondria creates distinct compartments in the 
organelle with specific functions. For example, space between the inner and outer 
membranes is relative isolated from mitochondrial matrix, and plays crucial roles in 
oxidative phosphorylation and ATP production. The mitochondrial matrix is the region 
surrounded by inner membranes, and it contains enzymes involved in tricarboxylic acid 
(TCA) cycle, fatty acid oxidation and mitochondrial DNA (mtDNA) replication [16]. 
         The primary function of mitochondria is to generate ATP to fulfill cellular energetic 
demands through oxidative phosphorylation in the respiratory chain. The TCA cycle in 
mitochondrial matrix serves as a central site that links to a wide variety of metabolic 
substrates generating acetyl-CoA, including carbohydrates, proteins and lipids. The TCA 
cycle oxidizes acetyl-CoA into carbon dioxide and water. Meanwhile, energy released 
from oxidation is saved in NADH, FADH2 and guanosine triphosphate (GTP). 
Subsequently, NADH is oxidized by NADH dehydrogenase (complex I) and recycled 
back as NAD+. The electrons donated from NADH are passed along a series of proteins 
and lipids, including coenzyme Q, cytochrome b/c1 (complex III), cytochrome c and 
cytochrome a/a3 (complex IV) and eventually donated to oxygen (1/2 O2) to produce 
H2O. This process has been referred as electron transport chain (ECT). Meanwhile, the 
energy released from NADH oxidation pumps protons into inner-membrane space and 
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creates a proton electrochemical gradient, which drives the synthesis of ATP from ADP 
by ATP synthase complex (Complex V). And this process has been identified as 
oxidative phosphorylation [6]. Generally, only a portion (30-40 %) of the energy from the 
NADH oxidation is used to generate proton gradient, the rest part is mainly released as 
heat. But, some proteins and proton channels allow the protons leaking back into the 
matrix and diminish the proton gradient. Higher expression of these proteins means that 
more NADH is required to maintain the proton gradient, and more energy is lost as heat. 
In humans, mitochondrial uncoupling accounts for approximately 25% of whole–body 
basal metabolism [16, 17]. There are 3 different types of uncoupling proteins (UCP) with 
tissue-specific distribution in mammals; UCP1 is mainly expressed in brown adipose 
tissue, UCP2 is expressed at high level in pancreatic islets and immune system, UCP3 is 
primarily expressed in skeletal muscle [6, 18].  
          Meanwhile, mitochondria also are involved in multiple cellular basic processes, 
such as urea production, heme biosynthesis, fatty acids β-oxidation, nucleotide synthesis, 
cell proliferation, differentiation and apoptosis [19, 20]. For example, mitochondria 
regulate cellular oxidative stress via reactive oxygen species (ROS) production and 
degradation [21]. Under physiological conditions, 0.2-2% of total oxygen uptake in 
mitochondria are converted to ROS, by direct passing electrons to O2 to generate 
superoxide anions (O2-) [22]. Most of the superoxide can be catalyzed to non-radical 
hydrogen peroxide (H2O2) by superoxide dismutase. But, ETC defects or excessive 
substrate in mitochondria results in higher ROS production through increased binding 
between overabundance electron and free oxygen, leading to impairment of 
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mitochondrial function [23]. Therefore, precise regulations of mitochondrial content, 
distribution and function are required for the maintenance of cellular homeostasis.  
           Mitochondrial biogenesis is a process of generating new mitochondria in cells in 
response to cellular stress, inflammatory signals and environmental changes [25] [26]. 
Multiple steps are involved in this process, such as mtDNA replication, mtDNA 
transcription and translation, structural proteins and lipids biosynthesis, nucleus-derived 
transcriptional factors translation, mitochondrial proteins import and assembling [27].  
          Compared to nuclear genome, mammalian mtDNA is a small circular double-
stranded DNA genome (~16.5 kb pairs) with limited coding capacity [28], which encodes 
only 13 respiratory complexes proteins, 2 rRNAs and 22 tRNAs [29]. Remaining 1000-
15000 essential proteins in mitochondria rely on nuclear genome encoding and 
mitochondrial import [30]. Therefore, coordinated expression of mtDNA and nuclear 
genomes are required to maintain the mitochondrial function and mitochondrial 
biogenesis [19]. The nucleus regulates mitochondrial biogenesis through several 
pathways, including encoding catalytic proteins components of mitochondrial enzymes, 
encoding transcription factors and co-activators that regulate mitochondrial biogenesis; 
and encoding proteins that are responsible for assembly, import and translocation of 
mitochondrial enzymes [31].  
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Figure 2-1 Mitochondrial biogenesis and the OXPHOS machinery. 
The protein complement of mitochondria consists of 13 subunits, encoded by mtDNA, 
which are synthesized in the organelle. The remaining proteins are encoded by nuclear 
genes and are made in the cytosol and imported into mitochondria. Inset: the OXPHOS 
machinery of the inner membrane consists of complexes I–IV, involved in electron 
transfer and proton export to the intermembrane space, whereas complex V uses the 
proton gradient to generate ATP. Uncoupling protein (UCP) uses proton flow to generate 
heat. Cytochrome c (red) is found in the intermembrane space. The total number of 
subunits encoded by nuclear and mtDNA are shown for each of the OXPHOS 
complexes. Adopted from Michael T. Ryan et al., 2001 [28]. 
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          Nuclear respiratory factor 1 and 2 (NRF1/NRF2) are the first isolated transcription 
factors that control mitochondrial genes expression in mammalian cells [19, 33]. NRF1 
regulates mitochondrial biogenesis by promoting expression of genes involved in 
mitochondrial transcription, protein import and assembly. NRF2 has been found to 
promote oxidative phosphorylation system (OXPHOS) enzyme expression [34]. 
Additionally, estrogen-related receptors α (ERRα) have been considered as key regulator 
in proliferation of mitochondria [26]. Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), a major inflammatory transcriptional factor, has been shown to 
promote anti-apoptosis by interacting with mitochondrial ATP/ADP translocator-1 
(ANT1), and decrease ETC activity via inhibition of cytochrome c oxidase III (Cox III) 
and cytochrome b (Cyt b) expression [35]. Signal transducer and activator of 
transcription 3 (STAT3) also has been reported to stimulate Complex I encoding, which 
further decreases mitochondrial ROS generation and protects against mitochondrial 
apoptosis [36].  
           Since NRF-1, ERRα and peroxisome proliferator-activated receptor (PPARα) have 
been demonstrated as direct targets of peroxisome proliferator-activated receptor gamma 
co-activator 1 (PGC-1) family [37], mitochondrial function and biogenesis appear to be  
highly associated with PGC-1α gene expression and activity [26].  
2.1.2   Roles of PGC-1α on mitochondrial biogenesis and function 
          PGC-1α belongs to PGC-1 coactivator family, which also contains PGC-1β and 
PRC with similar structure. 
          Originally, PGC-1α was identified in brown adipose tissue during adaptive 
thermogenesis as a binding protein of PPARγ under cold exposure [38]. Mechanistically, 
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PGC-1α co-activates PPARγ and induces UCP1 gene expression, resulting in increased 
heat production in brown adipocytes in response to cold stimuli [39]. Later, protein 
analysis indicated that PGC-1α served as a major regulator of mitochondrial biogenesis 
and oxidative metabolism via modulation of transcriptional factors and nuclear hormone 
receptors, such as NRF-1, ERRα, YY1, PPARα and MEF2C, in high energy demand 
tissues and organs, including brown adipose tissue, heart, skeletal muscle, kidney and 
brain [19]. By co-activating with PGC-1α, NRFs and ERRα not only bind to regulatory 
regions of genes involved in mitochondrial biogenesis, but also bind to other 
mitochondrial transcription factors promoter. Thus, PGC-1α modulates mitochondrial 
biogenesis and oxidative function via utilization of the transcriptional factors-related 
network [26]. 
          Activated PGC-1α triggers downstream effects in a tissue-specific manner. In the 
liver, PGC-1α markedly promotes gluconeogenesis to maintain whole body glucose 
homeostasis during fasting via increasing TCA cycle flux by inducting expression of 
phosphoenolpyruvate carboxykinase ( PEPCK)  and glucose-6-phosphatase [40]. In brown 
adipose tissue, as discussed above, PGC-1α induces UCP1 expression and coordinately 
modulates adaptive thermogenesis [39]. In skeletal muscle, PGC-1α is a potent regulator 
of glucose uptake, fatty acid oxidation and muscular fiber type switching [41]. For 
example, overexpression of PGC-1α in mouse skeletal muscle significantly increases 
mitochondrial biogenesis and mitochondrial oxidative function via promoting expression 
of cytochrome c oxidase subunit 4 and cytochrome c (Cyt C) [42], which subsequently 
induces muscular fiber characteristic change from type IIB fibers (fast glycolytic) into 
type I (slow oxidative fibers) with abundant mitochondria and higher endurance for 
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exercise [43]. Interestingly, PGC-1α also regulates energy metabolism in skeletal muscle 
[44, 45]. Physical exercise activates PGC-1α via phosphorylation and activation of 
AMPK, leading to increased adaptive oxidative metabolism in skeletal muscle [46]. In 
addition, PGC-1α plays an essential role in regulation insulin signaling in skeletal 
muscle. Decreased PGC-1α expression has been found in insulin resistant patients, 
associated with mitochondrial content loss and function impairments [47], whereas 
increased PGC-1α via exercise training rescues insulin resistance and glucose intolerance 
back to normal [48]. Moreover, evidences suggest that PGC-1α regulates oxidative and 
inflammatory stress in skeletal muscle. By promoting expression of superoxide 
dismutase-2, catalase, glutathione peroxidase 1 and uncoupling proteins, PGC-1α 
decreases the ROS production and facilitates its degradation, and protects mitochondrial 
proteins against oxidative stress [49]. 
         Since PGC-1α plays such important roles in energy metabolism, its expression and 
activity are strictly regulated by transcription factors and co-activators, protein 
kinases/phosphatases at both transcriptional and post-transcriptional levels [49]. At the 
transcriptional level, PGC-1α expression can be elevated by a wide range of factors in a 
tissue-dependent manner, such as cold exposure and beta-adrenergic signaling in brown 
adipose tissue, prolonged exercise and nutrient deficiency in skeletal muscle, fasting and 
calorie restriction in liver [50]. 
         Structurally, PGC-1α has an activation domain at the N-terminus, which normally 
modulated by steroid receptor coactivator 1 (SRC1) and cAMP response element binding 
protein (CREB) binding protein / p300 [51]. cAMP signaling serves as a key activator of 
PGC-1α transcription by prompting the binding between CREB and PGC-1α promoter 
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[52]. Also, PPARs has been considered as the major activators of PGC-1α in response to 
various external stimulations in skeletal muscle and brown adipose tissue [19]. 
Additionally, PGC-1α regulates its own expression in a positive auto-regulatory loop 
through activation of YingYang 1 (YY1), a common target of mTOR signaling [53]. At 
certain level, activated mTOR signaling leads to increases of YY1- PGC-1α transcription, 
which subsequently promotes mitochondrial biogenesis [52]. Interestingly, mTOR 
signaling modulates mitochondrial function in two different pathways: suppressed mTOR 
signaling activates fatty acid oxidation and promotes OXPHOS enzymes expression, 
which is accompanied by inhibition of cellular protein synthesis. In contrast, activated 
mTOR also stimulates mitochondrial biogenesis through mTOR-YY1- PGC-1α signaling 
pathway with few effects on protein biosynthesis [54].  
          In addition to the regulation of PGC-1α expression, its activity and stability are 
also highly controlled by posttranscriptional modifications, including phosphorylation, 
ubiquitination and acetylation [37]. In skeletal muscle, AMPK, p38 MAPK and protein 
kinase B (AKT) have been reported to active PGC-1α by changing phosphorylation status 
of residues at distinct sites of the protein [49]. AMPK directly phosphorylates threonine-
177 and serine-538 residues of PGC-1 α, and hereby induces PGC-1α activation, 
whereas, p38 MAPK phosphorylates PGC-1 α and stabilizes the protein [55]. Since PGC-
1α has a relative short half-life, extending the protein stability is an important mechanism 
to maintain PGC-1α activity [49]. Furthermore, PGC-1α is heavily acetylated in the 
whole sequence of protein, and decreased acetylation status of PGC-1α is highly 
associated with PGC-1α activation. Thus, acetyltransferase GCN5 and deacetylase SIRT1 
have been reported as key regulatory enzymes for PGC-1α [56]. For instance, by sensing 
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decreased cellular NAD+ level, activated SIRT1 promotes mitochondrial biogenesis and 
fatty acid oxidation to generate more ATP to rebalance the energy metabolism, partially 
through deacetylation and activation of PGC-1α [57]. In fact, recent data from resveratrol 
studies strongly support that AMPK and SIRT1 act synergistically on PGC-1α activation 
[58].  
2.1.3    Mitochondrial dysfunction and insulin resistance 
          Since mitochondria play such crucial roles in energy metabolism, inherent or 
acquired mitochondrial disorders can cause major disruption of cell survival and whole 
body metabolic homeostasis [6]. For example, defects in respiratory complex I lead to 
atrophy of optic nerve in adults; mutation of mitochondrial aminoacyl-transfer RNA 
synthestases (ARS2s), which is required for mitochondrial tRNA function, results in 
ovarian dysfunction and hearing loss [59]. Impaired mitochondrial oxidative function has 
been found in neuromuscular degenerative diseases, such as Alzheimer’s disease, 
Parkinson’s disease and some types of cancer [21]. Mitochondrial content loss strongly 
links to development of age-related diseases [24]. 
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Figure 2-2: Mechanism of mitochondrial dysfunction. 
Excess intake of nutrients, including overloaded FFAs or hyperglycemia conditions, 
increases ROS production and reduces mitochondrial biogenesis, causing mitochondrial 
dysfunction. Mitochondrial dysfunction leads to decreased β-oxidation and ATP 
production and increased ROS production, resulting in insulin resistance, diabetes, and 
cardiovascular disease. Adopted from Kim J.A et al., 2008[60] 
 
           In previous studies, mitochondrial dysfunction in skeletal muscle has been found 
in a number of chronic metabolic diseases, such as insulin resistance syndrome, obesity, 
cancer, and type 2 diabetes [61]. For example, reduced mtDNA and respiratory enzymes 
expression have been reported in insulin resistant individuals among obesity patients 
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[62]. Decreased mitochondrial density is strongly correlated to insulin resistance and 
glucose intolerance in type 2 diabetes patients [63]. 
         As a major anabolic hormone, insulin stimulates glucose uptake and mobilization, 
promotes synthesis of lipids and proteins, and inhibits gluconeogenesis primarily through 
IRS- PI3K-AKT-mTOR-FOXO1 signaling pathway [64]. While, insulin resistance is a 
pathological condition that cells fail to respond to hormone insulin normally [65].          
          Regards to the relationship between mitochondrial dysfunction and insulin 
resistance, previous studies provide multiple theories to explain the underlying 
mechanism. According to Befroy et al., genetic and environmental factors-induced 
mitochondrial defects are the main causes of insulin resistance. Decreased mitochondrial 
oxidation capacity and increased lipid intermediates accumulation, such as fatty acyl CoA 
and diacylglycerol, promote phosphorylation of Ser/Thr of IRS-1 through intracellular 
serine/threonine kinase cascades, resulting in impairment of insulin signaling [66]. 
Indeed, Zhang et al. demonstrated that long-chain acyl-CoA dehydrogenase mutation 
causes mitochondrial dysfunction, leading to diacylglycerol accumulation and insulin 
resistance in liver [67]. 
          However, some other studies suggest that excessive lipid accumulation is the 
reason rather than the consequence of mitochondrial dysfunction [9, 68]. For example, 
data from oligonucleotide microarray analysis reveal that feeding of HFD decreases 
expression of genes that are required for OXPHOS and mitochondrial biogenesis, such as 
NADH dehydrogenase 1 beta subcomplex 3 (NDUFB3), NDUFB5 and PGC-1α, leading 
to the impaired mitochondrial function in pre-diabetic and insulin resistance state patients 
[69].        
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          Interestingly, mitochondrial dysfunction might exhibit beneficial effects on insulin 
signaling under certain circumstances [70]. Evidence from Pospisilik et al. demonstrate 
that decreased mitochodnrial oxidative phosphorylation, which induced by targeted 
deletion of the mitochondiral flavoprotein apoptosis inducing factor (AIF), protects 
against HFD-induced obesity and insulin resistance in mice [71]. 
 On the other hand, mitochondrial biogenesis and oxidative capacity have been 
found elevated in skeletal muscle in type 2 diabetes patients and HFD-fed animals.[7]. 
However, the increased mitochondrial oxidative function might not be able to 
compensate the excessive fatty acid flux, resulting in accumulation of lipid metabolites 
that could be further oxidized into lipid peroxides in the mitochondrial matrix [68]. 
Unlike genomic DNA, mtDNA is sensitive and vulnerable to oxidative stress due to the 
lack of protective histones [72]; therefore, increased mitochondrial ROS promotes toxic 
impacts on mtDNA, RNA and mitochondrial proteins [73], leading to the impairments of 
mitochondrial function. Nabben et al. further support the role of ROS in mitochondrial 
dysfunction by showing that overexpression of UCP3 significantly decreases ROS level 
and blocks age-induced mitochondrial loss and insulin resistance in mouse skeletal 
muscle [73].  
 In addition, substrates competition in mitochondria might be another explanation 
for the lipid-induced insulin resistance [68]. The abundance of fatty acids in mitochondria 
tends to switch glucose oxidation into lipid oxidation, which aggravates glucose 
accumulation in both cytoplasm and circulation. Therefore, fatty acid oxidation blockers 
have been used as treatment for type 2 diabetes to lower the plasma glucose level. For 
example, etomoxir, an inhibitor of carnitine palmitoyltransferase 1 (CPT1), has been 
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found to decrease plasma glucose, increase GLUT4 translocation, and stimulate glucose 
uptake and mobilization by reducing fat oxidation in skeletal muscle [74].  
          Although the cause-and-effect relationship between mitochondrial dysfunction and 
lipid-toxicity remains uncertain [6], increased mitochondrial function and mitochondrial 
biogenesis may have beneficial effects on metabolic diseases. 
2.2 Roles of SIRT1 in energy metabolism 
2.2.1   Sirtuins overview 
          Calorie restriction (CR), normally identified as a diet contains all essential nutrients 
but with 20-40% less calorie intake compared to free fed diet, has been associated with 
multiple beneficial effects on aging and the onset of age-related diseases in a number of 
species, including worms, yeast, fish, mice and primates [75]. Genetic and molecular 
studies from different organisms indicate that CR is an actively regulated process, rather 
than a passive consequence of low-level calorie intake [76]. Although few studies have 
confirmed the CR effects on age-related diseases in humans, possibly due to the difficulty 
of complying with dietary changes, CR is highly associated with reduction of disease and 
mortality risk in a wide range species [94]. 
           SIR2 (Silent Information Regulator 2) in budding yeast Saccharomyces cerevisiae 
has been indicated as the main regulator mediating CR-induced metabolic changes and 
extending lifespan [77]. Overexpression of Sir2 and Sir2 activator treatment have been 
shown to prolong the replicative life span in S. cerevisiae via directly interaction with 
nucleosome histones, such as histone H4 lysine16 (H4K16), whereas, Sir2 functional 
mutants significantly cut down the lifespan [78]. Meanwhile, the histone-deacetylase 
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activity of Sir2 is highly dependent on intracellular NAD+ level, suggesting that Sir2 
might also play a part in the modulation of cell energy metabolism [79].  
          In mammals, SIRT1, the orthologue of Sir2, belongs to a conserved sirtuins family 
of protein deacetylases and mono-ADP-ribosyltransferases [77]. In protein deacetylation 
reaction, SIRT1 couples lysine residues deacetylation to NAD+ hydrolysis, which 
converts NAD+ into nicotinamide (NAM) and O-acetyl-ADP ribose [80]. Unlike yeast, 
mammalian sirtuins not only target histone, but also deacetylate other transcription 
factors, such as p53, FOX (Forkhead box) and PGC-1α [81]. The identification of cellular 
sirtuins substrates further supports the potential effects of sirtuins on a wide range of 
biological processes, including DNA repairing, oxidative stress responses, energy 
metabolism and cell apoptosis [82].  
          There are seven conserved members (SIRT1- SIRT7) in mammalian sirtuins family 
with distinct intracellular localizations, such as nucleus sirtuins (SIRT1, 2, 3, 6, and 7), 
cytoplasm sirtuins (SIRT1 and 2) and mitochondrial sirtuins (SIRT3, 4 and 5) [83]. The 
major function of these sirtuin are different from one-another: most sirtuins have NAD+-
dependent deacetylase activity, while Sirt4 and Sirt6 exhibit NAD+-dependent mono-
ADP-ribosyltransferase activity, whereas, Sirt7 has no observed deacetylase activity at all 
[84] [85]. 
2.2.2   Roles of SIRT1 in metabolic homeostasis 
          SIRT1 was first identified and most extensively studied Sir2 orthodox in mammals. 
In addition to mediating CR-induced extending lifespan, SIRT1 has been found to play an 
important role in modulation of energy metabolism [86]. For example, SIRT1 is required 
for the increases in physical activity observed during CR in mice [80]. Nisol et al. 
22	  	  	  
demonstrated that CR promoted mitochondrial biogenesis and SIRT1 expression in 
multiple tissues of male mice via endothelial nitric oxide synthase (eNOS)-dependent 
pathway [87]. Furthermore, overexpression of SIRT1 has been demonstrated to mimic 
CR-induced metabolic changes, including improved glucose tolerance and insulin 
sensitivity, decreased circulating triglycerides and cholesterol [83, 88]. 
          Mechanistically, there are mainly three pathways mediating SIRT1 regulatory 
effects on energy metabolism [83]. First, SIRT1 modulates chromatic function via direct 
deacetylation of histone, and leads to DNA translation changes. Additionally, SIRT1 can 
regulate acetylation status of transcription factors and coactivators, such as p53, NF-κB, 
PPAR-γ and PGC-1α, thereby, regulate target genes transcription. Finally, SIRT1 can 
directly deacetylate and activate target enzymes, leading to the controlling of cellular 
signaling [89]. 
          In lipid metabolism, activated SIRT1 primarily reduces fat accumulation. At 
transcriptional level, overexpression of SIRT1 decreases fat storage in WAT by reducing 
expression of genes involved in lipid synthesis, such as adipose tissue-specific fatty acid-
biding protein 2 (AP2), PPARγ, CCAAT/enhancer-binding protein α (C/EBP α) and 
C/EBPδ [90, 91]. SIRT1 activates and deacetylates FOXO1, a transcription inhibitor of 
PPARγ, resulting in increased hepatic gluconeogenesis and suppression of adipocyte 
differentiation [54, 91]. Moreover, studies have demonstrated SIRT1 promotes lipolysis 
to protect against HFD-induced obesity in mice through a complicated signaling cascade 
that involving in AMPK activation [58].  
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Figure 2-3 SIRT1 regulates metabolism in multiple tissues 
SIRT1 regulates the activity of critical transcriptional regulators of metabolism, including 
FOXO1, PPARα, PPARγ, and PGC-1α, in several organs. In the liver, SIRT1 
deacetylates and activates PGC-1α and interacts with FOXO1, which leads to activation 
of gluconeogenesis and decreased glycolysis. In muscle, SIRT1 activates PGC-1α, 
inducing mitochondrial biogenesis and increasing fatty acid oxidation. In white adipose 
tissue (WAT), SIRT1 represses the transcriptional activity of PPARγ, causing increased 
fat mobilization and decreased adipogenesis. In the pancreas, SIRT1 enhances insulin 
secretion by downregulating UCP2 expression. The expression and biological activity of 
SIRT1 are activated during fasting and calorie restriction (CR) and in response to 
resveratrol. It should be noted that resveratrol has other cellular targets, such as AMPK, 
which could mediate some of its biological activities. Adopted from Schwer et al., 2008 
[83] 
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          Paradoxically, SIRT1 also has been found to activate and deacetylate acetyl-CoA 
synthetase (AceCS), a key enzyme for lipid synthesis in response to SREBPs and insulin, 
leading to increases of fatty acid synthesis from acetate. There are two AceCSs in 
mammals: cytoplasmic AceCS1 and mitochondrial AceCS2. SIRT1 could deacetylate 
mouse AceCS1 on Lys-661 site and subsequently lead to activation of AceCS1, resulting 
in a pronounced increase in fatty acid production via AceCS1-dependent pathway [92]. 
          SIRT1 also contributes to the modulation of glucose metabolism in a tissue-
specific manner. Under fasting and CR condition, the liver provides glucose as a fuel to 
other organs and maintains circulating glucose homeostasis via gluconeogenesis [93]. 
SIRT1 activity and expression level are highly elevated during CR and promote hepatic 
glucose metabolic shift from glycolysis into gluconeogenesis via activation of PGC-1α 
and FOXO, resulting in significant increased release of glucose [91]. Specific hepatic-
SIRT1 knockout attenuates glucose output, and subsequently induces mild circulating 
hypoglycemia and free fatty acid accumulation in liver [93]. In skeletal muscle, SIRT1 
also activates PGC-1 α to switch the cell fuel utilization from glucose oxidation to fatty 
acid oxidation in response to fasting, associated with up-regulated mitochondrial 
biogenesis and oxidative function [57].  
          Meanwhile, SIRT1 has been found to regulate glucose homeostasis through 
modulation of insulin secretion. Pancreatic β-cell is the only source of insulin production 
and secretion, and its dysfunction causes hyperglycemia and insulin resistance [93]. 
Insulin secretion in pancreatic β-cells strongly depends on intracellular ATP/ADP ratio 
and UCP2 expression: increased glucose uptake in the β-cells stimulates ATP production, 
which triggers insulin releases from the cell by exocytosis. Increased UCP2 diminishes 
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the mitochondrial inner-membrane gradients and subsequently decreases ATP synthesis, 
resulting in suppression of insulin secretion [94]. SIRT1 has been found to directly bind 
to and inhibit UCP2 promoter, leading to decreased UCP2 protein expression and 
subsequent increased insulin releases [95]. Genetic forced expression of SIRT1 in 
pancreatic β-cells results in significant improvement of glucose tolerance, associated with 
reduced UCP2 expression and increased insulin secretion in HFD mice [96], while, 
SIRT1 siRNA markedly attenuates these effects.  
           In addition to UCP2, some transcriptional factors, such as NF-κB, PPARγ, 
FOXO1 and PGC-1α also have been implicated in SIRT1 effects in β-cells [83]. For 
example, SIRT1 protects pancreatic β-cells against acute oxidative stress by deacetylation 
and activation of FOXO1 [97]. Similarly, SIRT1 activation induced by resveratrol has 
been found to promote insulin secretion in an UCP2-independent pathway in INS-1E beta 
cells and human islets [98]. 
           SIRT1 also stimulates insulin sensitivity in peripheral tissues to maintain the 
metabolic homeostasis. For example, activated SIRT1 increases GLUT4 translocation, 
thereby, stimulates glucose uptake in skeletal muscle cells. SIRT1 suppresses protein 
tyrosine phosphatase 1 B (PTP1B), an inhibitor of insulin signaling, through a PGC-1α 
dependent pathway, resulting in increased insulin sensitivity in HFD mice [99]. 
2.2.3   Roles of SIRT1 in mitochondrial biogenesis and function 
        The content and function of mitochondria are highly associated with the balance 
between cellular energy requirements and the ATP production. By sensing decreased 
intracellular NAD+ level, activated SIRT1 promotes mitochondrial biogenesis and 
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function, at least in part, through activation of PGC-1α to maintain intracellular energy 
homeostasis in response to environmental changes [100].  
         In yeast, worms and flies, Sir2 has been reported to mediate CR-induced increases 
in mitochondrial biogenesis, oxygen consumption and ATP production [87, 101]. 
Overexpression SIRT1 increases whole-body metabolic efficiency and protects against 
HFD-induced metabolic abnormalities in mice [102]. In human, CR has been proved to 
promote muscle mtDNA replication in association with elevated SIRT1, PGC-1α and 
TFAM expression [103]. Similar results also have been found in SIRT1 activators 
studies. Resveratrol, an activator of SIRT1, could mimic CR effects on energy 
metabolism by promoting mitochondrial biogenesis and mitochondrial regulatory 
proteins in mice [89]. 
           Prolonged exercise has been demonstrated to promote mitochondrial oxidative 
capacity and mitochondrial content in skeletal muscle, but whether SIRT1 expression is 
also elevated during exercise and proportional to the mitochondrial function and content 
is an unanswered question. For example, soleus muscle contains less mitochondrion but 
higher SIRT1 protein at baseline than heart cells [104]. In fact, evidence from Gurd et 
al.’s study shows that SIRT1 is not associated with mitochondrial oxidative function 
[105]. Overexpression of SIRT1 decreases mitochondrial biogenesis in heart and skeletal 
muscle in rat in response to exercise [105]. Genetic SIRT1 knockout mice exhibit normal 
mitochondrial content and function in skeletal muscle compared to the wild-type controls, 
suggesting that other signaling pathways may contribute to the maintenance of 
mitochondrial biogenesis [106]. 
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         However, some studies demonstrate that SIRT1 is positively correlated to 
mitochondrial biogenesis in rat skeletal muscle [107]. Increased SIRT1 activity has been 
found in rat skeletal muscle with chronic electrical stimulation and cold exposure [104]. 
In addition, elevated SIRT1 expression has been found to rescue the age-induced 
mitochondrial content loss in Wistar rats [108]. 
          SIRT1 regulates mitochondrial biogenesis primarily through two pathways: 
modification of transcriptional level of genes involved in mitochondrial biogenesis, and 
directly deacetylation of enzymes in the mitochondria. Deacetylated and activated PGC-
1α, a direct target of SIRT1, controls mitochondrial biogenesis and function via 
regulating transcription of the nuclear and mitochondrial genome as we discussed above 
[109]. For example, resveratrol increases SIRT1 activity and mitochondrial biogenesis, 
associated with increased acetylation and activation of PGC-α in HFD mice [110]. In 
addition, SIRT1 directly deacetylates and suppresses hypoxia-induced factor 1α (HIF1 α), 
a key transcription factors that inhibits the TCA cycle, resulting in significant increases of 
mitochondrial oxidative capability and attenuation of glycolysis [111]. 
          At post-translational level, most of the enzymes involved in TCA cycle, fatty acid 
oxidation and oxidative phosphorylation in mitochondrial are highly acetylated. Data 
from proteomic survey demonstrate that 511 lysine residues in proteins of ETC are 
modified by acetylation [112]. Therefore, SIRT1 may modulate these enzymes activity 
through direct deacetylation and thereby regulate mitochondrial oxidative function [98, 
110]. For example, AceCS2, a mitochondrial matrix protein, can be reversibly acetylated 
at Lys-642 and subsequently activated by mitochondrial sirtuins [113]. On the other hand, 
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SIRT1 and SIRT3 knockouts markedly attenuate mitochondrial function, and lead to 
suppression of ATP production in many tissues of mice [110]. 
2.2.4   Regulation of SIRT1 expression and activity 
        SIRT1 modulates multiple cellular fundamental processes by serving as the key 
regulator of energy metabolism. However, the regulation of the SIRT1 enzyme itself, 
including the gene expression and activity, is still not fully elucidated. 
          At gene expression level, CR is a strong environmental stimulus to promote SIRT1 
expression in many species. In both primates and rodents, CR increases SIRT1 protein 
levels in many tissues, including brain, heart, kidney and skeletal muscle [114]. 
Similarly, elevated SIRT1 expression also has been found under many other nutrient 
deprivation statuses, such as fasting and prolonged physical exercise [115]. CR-induced 
SIRT1 expression occurs in a tissue-dependent manner, particularly in liver. Chen et al. 
indicate that both CR fed and high-calorie diet could increase SIRT1 protein level in liver 
in mice [116], suggesting more complex mechanism underlies the SIRT1 regulation.  
          Mechanistically, the molecular signaling pathways of SIRT1 gene transcription are 
not fully understood. Nemoto et al. demonstrate that increased intracellular NAD+ losses 
the binding between redox sensor transcriptional corepressor CtBP (Carboxylterminal 
binding protein) and transcriptional repressor HIC1 (Hypermethylated in Cancer), and 
leads to the opening of the SIRT1 promoter site for other transcriptional factors, such as 
FoxO3 and p53, resulting in increased SIRT1 expression[115]. Cellular oxidative and 
inflammatory stress also appears to play a part in the regulation of SIRT1 expression and 
activity. For example, Wu et al. report that HFD-induced oxidative stress in cerebellar 
cells significantly decreases SIRT1 expression, and vitamin E supplementation markedly 
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reverses this down-regulation effect [117]. In mouse cardiac muscle, overexpression 
SIRT1 protects against oxidative stress-induced cardiomyopathy via decreasing ROS 
production by promoting expression catalase. But high-level ROS could decrease SIRT1 
expression and trigger cardiac pathology [118]. 
           Cellular NAD+ level or NAD+/NADH ratio is the major regulator of SIRT1 
activation. There are two NAD+ biosynthesis pathways in mammalian cells, de novo and 
salvage pathways. NAD+ synthesized via de novo pathway uses L-tryptophan as the 
precursor through multiple steps. The salvage pathway uses nicotinamide (NAM) or 
nicotinic acid (both of them called niacin or vitamin B3) to produce NAD+, catalyzed by 
two rate-limiting enzymes: nicotinamide phosphoribosyltransferase (NAMPT) and 
nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) [89, 119]. Therefore, 
SIRT1 activity is highly associated with the expression and activity of NAMPT and 
NMNAT-1 [89]. For example, in myoblasts, elevated NAMPT expression increases 
cellular NAD+/NADH ratio and stimulates SIRT1 activity, leading to a SIRT1-dependent 
attenuation of cell differentiation [120]. Similar results have been found in human 
vascular smooth muscle cells (SMCs), that increased NAMPT expression and SIRT1 
activity have been found during cell maturation [121]. Moreover, NAMPT is implicated 
in SIRT1-dependent regulation of the circadian rhythm in mice [122]. In addition to 
NAMPT, NMNAT-1 also has been reported to regulate SIRT1 and subsequently protect 
neuronal cells against oxidative stress in Wallerian degeneration slow (WIdS) mouse 
model [123, 124].   
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Figure 2-4 Mammalian NAD+ biosynthetic pathways. 
The de novo pathway uses l-tryptophan as the precursor for NAD+ production in a multi-
step pathway. The salvage pathway uses nicotinamide or nicotinic acid (together called 
niacin or vitamin B3) to make NAD+. In addition, nicotinamide riboside has been identified 
as a dietary precursor for NAD+ biosynthesis. QPRTase, quinolinic acid 
phosphoribosyltransferase; NPT, nicotinic acid phosphoribosyltransferase; NMNAT, 
nicotinamide/nicotinic acid mononucleotide adenylyltransferase; NAMPT, nicotinamide 
phosphoribosyltransferase; NADS, NAD synthase, NRK, nicotinamide riboside kinase. 
Adopted from Zhang, T et al., 2010 [89] 
 
           Furthermore, poly (ADP-ribose) polymerase 1 (PARP-1), a NAD+-dependent 
chromatin and transcription-regulating enzyme, has been demonstrated to inhibit SIRT1 
activity by competition for intracellular NAD+ [125, 126]. For instance, increased 
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genotoxic stress activates PARP-1, which subsequently exhausts intracellular NAD+, 
leading to the suppression of SIRT1 activity [77]. 
 SIRT1 and its homology Sir2 share a common deacetylase domain with 
approximately 250 amino acids, which are highly phosphorylated at both N- and C- 
termini [127]. The crystal structure of Archaeoglobus fulgidi Sir2 reveals that the 
catalytic core of SIRT1 consists of a Rossmann fold and a small zinc-binding segment. 
Polypeptide substrates are captured in the cleft of these two segments and further 
deacetylased at acetyl-Lys residues. Meanwhile, NAD+ binds to the cleft and goes 
through hydroxylation at each Lys residue during deacetylation [128]. EX527, a SIRT1 
specific inhibitor, has been found to displace NAD+ from the binding site, promote 
SIRT1 enzyme structural conformation and prevent substrate binding, leading to 
inhibition of SIRT1 activity [128]. Accordantly, most pharmacological activators of 
SIRT1 appear to facilitate the process of NAD+ or peptide substrate binding to the 
enzyme [129].  
          Studies have identified a group of small molecules that could activate SIRT1 and 
mimic the CR effects as a promising therapeutic tool in the treatment of metabolic 
diseases, referred as sirtuin-activating compounds (STACs). Among these STACs, 
resveratrol has been studied most intensely. In 2003, Konrad et al. first reported three 
classes of sirtuin activators, including resveratrol, sharing a similar trans-stibene ring 
structures [101], which has been identified as an essential structure for SIRT1 allosteric 
conformation and activation [130]. 
           Although some studies have challenged the direct activation theory of resveratrol 
on SIRT1 enzyme, abundant data indicate that resveratrol and some other STACs, 
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including SRT1460, SRT1720 and SRT2183, bind to SIRT1 N-terminal domain and 
promote an allosteric conformation change of the enzyme-peptide substrate complex, 
leading to the decreases of Michaelis constant of SIRT1 for acetylated substrates and 
NAD+ [101, 131]. 
2.3   Roles of AMPK in energy metabolism 
          AMPK is an evolutionary conserved enzyme comprising of three subunits in most 
species, including a catalytic subunit (α) and two regulatory subunits (β and γ). AMPK 
serves as a crucial regulator of cellular energy metabolism by sensing intracellular ATP 
level or AMP/ADP ratio [132]. Increased AMP directly binds to γ subunit of AMPK and 
further promotes the enzyme self-conformation to expose Thr-172 (a threonine residue) 
in the α subunit, allowing AMPK upstream kinases, such as LKB1 and CaMKK β 
(calmodulin-dependent protein kinase kinase β), further phosphorylate and activate the 
enzyme. The binding of AMP to γ subunit also prevents AMPK dephosphorylating and 
keeps its activation status [133, 134].      
          LKB1 was initially identified as tumor suppressor in Peutz-Jeghers syndrome by 
inhibiting cell growth and proliferation via activation of AMPK signaling pathway [135], 
and its mutation results in significant susceptibility to human cancers [136]. LKB1 is 
strictly regulated at both transcriptional and post-translational levels. For instance, 
activated SIRT1 has been reported to deacetylate and activate LKB1, resulting in LKB1 
translocation from nucleus into cytoplasm [137]. Unlike LKB1, CaMKK β-mediated 
AMPK activation depends on increase of cytosolic Ca2+, which caused by multiple 
cellular ATP-consuming processes, such as nutrient transportation, muscle contraction 
and exocytosis, without elevation of AMP [138].  
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          Once activated, AMPK promotes a cellular metabolic switch from ATP-consuming 
anabolic pathways into more ATP-producing catabolic pathways, including promoting 
glucose and fatty acids uptake and oxidation while decreasing lipid, glycogen and protein 
synthesis and inhibiting cell growth and division [132]. Therefore, metabolic stresses that 
decrease cellular ATP content generally could activate AMPK, such as hypoxia, 
ischemia, low nutrients, oxidative stresses and prolonged exercise [139, 140]. Also, 
AMPK is sensitive to hormones and pharmacological molecules, such as leptin, 
adiponectin, AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) and 
metformin [135]. 
           In the regulation of carbohydrate metabolism, AMPK stimulates glucose uptake in 
both skeletal muscle and white adipose tissue by increasing the glucose transporter 
GLUT4 translocation from cytoplasm to plasma membrane through Rab GTPase-
activating protein (RabGAP)-dependent pathway [141]. Recent studies indicate that 
activated AMPK phosphorylates AS160 at some sites as AKT/PKB in insulin signaling, 
suggesting that insulin and AMPK might act synergistically at GLUT4 translocation and 
glucose uptake [142]. Activated AMPK also reduces glycogen synthesis via direct 
phosphorylation and suppression of glycogen synthases, and increases glycolysis by 
activation of 6-phosphofructo-2-kinase (PFK-2), leading to higher ATP production in a 
short-time period [143]. 
          Regards to lipid metabolism, AMPK inhibits lipids synthesis via direct 
phosphorylation and suppression of acetyl-CoA carboxylase (ACC1/ACC2) and HMG-
CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase), which are the rate-limiting 
enzymes for fatty acid and cholesterol biosynthesis, respectively [144]. Additionally, 
34	  	  	  
AMPK promotes fatty acids oxidation by phosphorylation and activation of carnitine 
palmitoyltransferase (CPT1). CPT1 regulates long-chain fatty acid oxidation in skeletal 
muscle by accelerating long-chain acyl-CoA flux into mitochondria. In this process, 
malonyl-CoA, synthesized by ACC at the first step of lipid production, serves as an 
allosteric inhibitor of CPT1 and blocks the long chain fatty acids flux [145]. AMPK 
decreases malonyl-CoA level by direct activation of malonyl-CoA decarboxylase (MCD), 
which is a malonyl-CoA catabolism-promoting enzyme [146]. Therefore, AMPK not 
only phosphorylates and inhibits ACC to decrease fat synthesis, but also reduces the 
production of malonyl-CoA to promote lipids oxidation. Furthermore, AMPK could 
directly activate lipases in fat tissue, including hormone-sensitive lipase (HSL) and 
adipocyte-triglyceride lipase (ATGL), and thereby promote lipolysis [147].  
          In addition to the direct acute modulation of key metabolic enzymes, AMPK is also 
involved in long-term adaptive lipids metabolic reprogramming through modulation of 
transcriptional factors, such as SREBP1 and PGC1-α [148]. Activated SREBP1 induces 
expression of multiple target genes involved in lipogenesis, such as ACC1 and FASN 
(fatty acid synthase), resulting in increased lipid synthesis not only in liver and other 
metabolic tissues, but also in all dividing cells [149]. AMPK has been demonstrated to 
directly phosphorylate a conserved site of SREBP1 and inhibit the SREBP1 expression, 
leading to decreased lipid biosynthesis [148].  
 Protein synthesis is an energy consuming process; therefore, it is not surprising 
that AMPK exhibits attenuation effects on protein metabolism. AMPK blocks the mTOR 
signaling, a major regulator promoting protein synthesis, via phosphorylation of TSC1-
TSC2 (tuberous sclerosis 2) complex [150]. AMPK phosphorylates and activates the 
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TSC1-TSC2 complex, which inhibits mTORC1 activity via suppression of Rheb, to 
promote their negative effects on mTOR signaling and blocks the protein synthesis [151]. 
          AMPK activation also attenuates cell growth and proliferation in mammals. 
AICAR-activated AMPK has been demonstrated to suppress cell growth by blocking cell 
cycle through p53-dependent pathway in cancer cell lines [152]. Besides promoting cell-
cycle arrest, AMPK suppresses cell divides, partially through the classical effects on 
inhibition of lipids and protein synthesis [153].  
          Furthermore, AMPK appears to stimulate ATP production not only by promoting 
fatty acid flux into mitochondria, but also by inducing mitochondrial biogenesis and 
oxidative function. Previous studies show that activated AMPK induces transcription of 
mitochondrial genes, including CPT1, FABP3 and acyl-CoA oxidase (ACO), resulting in 
higher mitochondrial biogenesis and increased exercise endurance in skeletal muscle cells, 
while specific AMPK knockout blocks these effects [169]. Although, mechanisms 
underlying AMPK promoting mitochondrial biogenesis are still unclear, PGC-1α has 
been considered as the major target and mediator of AMPK [170]. Jager et al. 
demonstrate that PGC-1α phosphorylation is the initial step of many AMPK-induced 
regulatory effects on energy metabolism, such as increased mitochondrial biogenesis, 
glucose uptake and fatty acid oxidation [55]. Interestingly, AMPK-induced 
phosphorylation of PGC-1α does not change its co- factor activity; instead, it releases 
PGC-1α from the repressor proteins and allows subsequent modification, such as SIRT1-
induced deacetylation and activation [58].  
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2.4   SIRT1 and AMPK interaction  
          Both SIRT1 and AMPK detect energy deficits and regulate cellular responses to 
maintain energy balance. Therefore, it is not surprising that some downstream substrates 
and signaling pathways of SIRT1 and AMPK overlap. In fact, mutual interactions 
between SIRT1 and AMPK have been found in a wide number of tissues and cell types, 
including liver, skeletal muscle and neuronal cells [132].  
          Initially, AMPK was considered as an upstream regulator of SIRT1 by increasing 
intracellular NAD+ level via promoting Nampt expression. In skeletal myoblasts, low 
glucose treatment activates AMPK and causes SIRT1-dependent impairment of cell 
differentiation. AMPK activation markedly increased expression of NAD+ biosynthetic 
enzyme, Nampt, which consequently increases NAD+/NADH ratio and NAD+ level. This 
increase in NAD+ activated SIRT1, which subsequently inhibited skeletal myogenesis via 
related gene transcriptional regulation [154]. Evidence from SIRT1 knockout mice shows 
that the expression of AMPK-target genes, such as UCP2, UCP3 and PDK4, are reduced 
with the absence of SIRT1 during fasting, indicating that SIRT1 regulates metabolic gene 
expression coherently with AMPK in skeletal muscle [120]. Consistently, recent evidence 
indicates that resveratrol activate SIRT1 through cAMP-AMPK-NAD+ signaling pathway 
in skeletal muscle in HFD-mice [155]. 
          However, activated SIRT1 also has been reported to regulate lipid metabolism by 
activating AMPK in liver via LKB1, suggesting that SIRT1 might serve as the upstream 
signal in this axis [143]. In addition, resveratrol-induced activation of SIRT1 decreases 
lipid accumulation and protects against HFD-induced obesity in mice,  
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Figure 2-5: The hypothetical SIRT1/AMPK cycle and its significance. 
A decrease in energy state or activation of AMPK by other means leads to activation of 
SIRT1, perhaps by increasing NAD+ or the NAD/NADH ratio and/or the activity of Nampt. 
SIRT1 then deacetylates and activates LKB1, which in turn activates AMPK. 
Alternatively, these events could be set in motion by factors that primarily increase 
SIRT1. The joint activation of SIRT1 and AMPK allows for the concurrent deacetylation 
and phosphorylation of the listed target molecules and presumably others. The predicted 
result would be a decreased susceptibility to metabolic syndrome-associated disorders 
and possibly delayed aging. Not shown is that a primary downregulation of SIRT1 or 
AMPK would presumably have opposite effects and predispose to the metabolic 
syndrome and accelerated aging. Adopted from Ruderman N. B et al., 2010 [158] 
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, primary via LKB1-dependnet activation of AMPK [156]. Moreover, forced 
overexpression of SIRT1 significantly stimulates AMPK signaling in HepG2 cell line and 
mouse liver [157]. 
2.5    Leucine 
2.5.1    BCAAs overview 
          According to the recommended daily allowance (RDA), 0.8 g protein/kg body 
weight/day (~70g/d) of dietary protein intake is recommended for healthy adults to 
maintain minimum level of nitrogen balance [159]. There are three amino acid members 
in branched chain amino acid (BCAA) group: leucine, valine and isoleucine [160]. The 
BCAAs have been implicated in many cellular metabolic processes beyond serving as 
essential substrates for new peptide synthesis. The roles BCAA play include regulating 
protein translation initiation, modulating insulin-PI3K signaling cascade, serving as a 
major nitrogen donor for alanine and glutamine, and a fuel for oxidation to generate ATP 
[161, 162]. Recently, evidence suggests that BCAAs might contribute to modulation of 
food intake and energy balance in central nervous system [163].  
          Interestingly, unlike the other 17 amino acids that are predominantly catabolized in 
liver, circulating BCAA levels stay unchanged after passing through the liver, possibly 
due to low expression levels of hepatic BCAA catabolic enzymes [161]. Therefore, 
BCAA concentrations in plasma and peripheral tissues, such as skeletal muscle and 
adipose tissue, are strongly dependent on dietary intake [160]. Accordingly, the potential 
effects of BCAAs on protein metabolism, insulin signaling and alanine and glutamine 
production are increased by higher BCAAs concentrations in skeletal muscle [164].  
39	  	  	  
2.5.2   BCAAs metabolism 
          In skeletal muscle, BCAA catabolism initially undergoes two steps, which are 
catalyzed by branched-chain amino transferase (BCAT) and branched-chain α-keto acid 
dehydrogenase (BCKDH) complex [165]. BCAT isozymes, including mitochondrial and 
cytosolic BCAT, catalyze reversible transamination reaction of BCAAs and transfer the 
BCAAs from the α-amino group into α-ketoglutarates: α-ketoisocaproic acid (KIC) for 
leucine, α-keto-β-methylvaleric acid (KMV) for isoleucine, and α-ketoisovaleric acid 
(KIV) for valine [161]. These keto acids of BCAA can subsequently be oxidized through 
the oxidative decarboxylation reaction by the BCKDH complex or released into 
circulation and taken up again by other organs, such as liver and adipose tissue, where 
they can be resynthesized into BCAAs or completely oxidized as fuels to generate ATP 
[161]. The BCKDH complex is comprised of three different enzymes, including a 
branched-chain α-keto acid decarboxylase (E1), dihydrolipol transacylase (E2) and 
dihydrolipoyl dehydrogenase (E3). The complex activity is regulated by BCKDH 
phosphatase and kinase by changing phosphorylation status of the E1 α subunit, leading 
to the modulation of BCAAs metabolism [166]. 
2.5.3   Roles of leucine in protein synthesis 
          Leucine is well known for its potential effect on promoting skeletal muscle protein 
synthesis under catabolic conditions, such as fasting, calorie restriction and prolonged 
exercise [167]. Leucine supplementation alone or combined with valine and isoleucine 
has been found to stimulate muscle protein anabolism in both rodent and human models 
[168-170]. In addition, short-term high doses (3 to 7 g) of leucine infusion have been 
demonstrated to reduce protein breakdown without changing protein synthesis rate [169]. 	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          The molecular mechanism for leucine-induced protein synthesis has been well 
established in many previous studies. mTOR, a conserved Ser/Thr kinase, has been 
considered as the major mediator for leucine-induced protein synthesis [171]. mTOR was 
initially found as the target of rapamycin, a macrolide with broad antiproliferative 
capabilities, and interacts with several other regulatory proteins to form two distinct 
complexes named mTOR complex 1 and 2 (mTORC1 and mTORC2) [172]. Compared to 
mTORC2, studies have focused more on mTORC1 signaling and functions. Besides 
amino acids, at least four major environmental factors modulate mTORC1 pathways, 
including growth factors, stress, energy condition and cellular oxygen status [173]. In fact, 
amino acids are so importation for mTOR signaling, that the absence of amino acids, 
especially leucine and glutamate, markedly attenuates growth factors-induced mTORC1 
activation [174]. The mTORC1 promotes protein translation initiation by phosphorylation 
and activation of translation factors, such as eukaryotic translation initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1). In contrast, inhibition of 
mTORC1, such as ATP-competitive mTOR inhibitor treatment, dramatically decreases 
protein synthesis, and subsequently impairs cell growth and proliferation [175].  
          Leucine activates mTOR kinase and promotes phosphorylation of eukaryotic 
initiation factor 4 complex and dissociates from its binding protein, leading to the 
activation of eIF4E. Activated mTOR also activates p70S6 kinase and then 
phosphorylates S6 ribosomal proteins. Additionally, leucine activates a second initiation 
factor, eukaryotic initiation factor-4G (eIF4G), via mTOR-independent pathways [176]. 
Therefore, leucine induces the activation of these tranlational factors and promotes 
translation initiation and protein synthesis [171, 176]. 
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Figure 2-6: Regulation of protein synthesis by branched-chain amino acids in vivo. 
The diagram outlines the mechanisms through which in vivo administration of BCAAs 
enhances the initiation phase of mRNA translation. The details are discussed in the text. 
PKB, protein kinase B; mTOR, mammalian target of rapamycin protein kinase; eIF, 
eukaryotic initiation factor; 4E-BP1, eIF4E binding protein-1; S6K1, 70-kDa ribosomal 
protein S6 protein kinase; S6, ribosomal protein S6; TOP, terminal oligopyrimidine tract; 
and UTR, untranslated region. Adopted from Yoshizawa F. et al., 2004 [176]. 
 
          However, the mechanisms of leucine activating mTOR signaling are poorly 
understood.  Du et al. suggest that leucine activates mTOR signaling partially through 
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AMPK inhibition by reducing intracellular AMP/ATP ratio [177], while others report a 
direct interaction between leucine and mTORC1. 
2.5.4   Roles of leucine in glucose regulation and insulin resistance 
          Unlike the regulatory effects on protein synthesis, the impacts of leucine on 
glucose homeostasis are still controversial, with studies suggesting both improving and 
worsening of insulin sensitivity.  
          In some studies, leucine has been found to stimulate hepatic glucose output, 
increase fasting glucose level, and aggravate glucose intolerance. Under physiological 
conditions, increased BCAAs intake promotes its own degradation in skeletal muscle, 
and results in increased production of alanine/glutamine, which subsequently participate 
hepatic gluconeogenesis in liver [161]. According to Ahlborg and colleagues, over 40% 
of endogenous glucose input depends on this glucose-alanine cycle during prolonged 
exercise [178], and BCAA-related hepatic gluconeogenesis accounts for 70% of glucose 
releases in liver during overnight fasting [179]. 
          Meanwhile, BCAAs also have been demonstrated to impair the whole body 
glucose tolerance through blocking insulin signaling in peripheral tissues and pancreatic 
β-cells. Rachdi et al. found leucine supplementation during pregnancy not only increased 
fetal body weight, plasma glucose and insulin, but also decreased pancreatic endocrine 
progenitor cells differentiation and β-cell formation via activation of mTOR-HIF1α 
signaling [180].  
         Increased circulating BCAA levels have been found in both insulin resistant 
animals and humans. Newgard et al. demonstrate that BCAAs and their related 
metabolites are markedly associated with insulin resistance compared to many lipids, 
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which have been considered as the major stimuli to promote insulin resistance [11]. They 
found that HFD with BCAA supplementation in Wistar rats reduced food intake and 
body weight, but also led to greater insulin resistance than HFD alone. In addition, cross-
sectional observations and interventional studies further support the connection between 
BCAAs and insulin resistance. Tai et al. found increased alanine, valine, leucine and 
isoleucine to be significantly associated with insulin resistant risk factors, such as fatty 
acids and inflammatory cytokines, in 263 non-obese Asian-Indian and Chinese men [181]. 
The baseline of BCAAs is positively correlated to insulin resistance in healthy children, 
leading to over 5-fold higher risk to develop type 2 diabetes [182].  
          According to the BCAA metabolic pathways, the increased plasma BCAAs in 
insulin resistant models are highly dependent on decreased BCAAs catabolic rate in 
peripheral tissues, particularly adipose tissue [166]. Although the reason is still unknown, 
decreased expression levels of BCAT and BCKDH complex have been found in adipose 
tissue compared to the lean controls, accompanied by significant increase of plasma 
BCAAs in obese rodent models [163]. Similar results were also found in human subjects 
[183]. 
          Under over-nutrient conditions, such as obesity and type 2 diabetes, mTORC1 
activity and expression are highly promoted in response to elevated circulating insulin, 
cytokines, BCAAs and glucose. On the other hand, activated mTORC1 impairs insulin 
signaling through phosphorylation S6K1- IRS-1 pathways. For example, BCAAs, 
particularly leucine, have been reported to activate p70 ribosomal S6 kinase (p70S6K) 
and S6K through mTORC1. Activated S6K subsequently phosphorylates serine/threonine 
residues of IRS-1, leading to the inhibition and degradation of IRS-1, and consequently 
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blocks insulin signaling [166, 184]. This leucine-induced IRS-1 phosphorylation pathway 
has been found in wide range of cell types, such as 3T3L1 adipocytes, L6 myotubes, and 
skeletal muscle of rat [185]. Notably, Tremblay et al. found that amino acid infusion-
induced insulin resistance in human was also mediated through the mTOR-p70S6-S6K1-
IRS1-phosphorylation cascade [186]. Not surprisingly, leucine-deficient diet has been 
found to significantly rescue the insulin sensitivity in mice [187], and S6K1 deficient 
mice are protected against this BCAA-induced obesity and insulin resistance [188]. 
          Furthermore, recent evidence suggests that AMPK and general control 
nonderepressible (GCN2) might also contribute to leucine-induced insulin resistance. 
GCN2 is the intracellular amino acid sensor and serves as upstream inhibitor of mTOR to 
suppress global protein synthesis [189]. According to Xiao et al., absence of leucine in 
liver not only activates GCN2 to inhibit mTOR signaling, leading to maintenance of 
insulin action, but also decrease lipogenesis through suppression SREBP-1c to reduce 
lipid synthesis, resulting in subsequent increases in insulin sensitivity indirectly [166, 
187]. 
 In contrast to these reports, some other studies demonstrate that BCAAs, 
particularly leucine, mediate beneficial effects on energy metabolism, especially, on 
insulin signaling. For example, Yzamin et al. found that doubling dietary leucine intake 
significantly reversed many HFD-induced metabolic abnormalities and increased glucose 
tolerance and insulin sensitivity in mice despite an increase in phosphorylation of IRS1 
[190]. Similarly, Zhang et al. demonstrated that increasing dietary leucine intake 
markedly decreased diet-induced obesity, hyperglycemia and hypercholesterolemia in 
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mice [191]. Furthermore, Nairizi et al. demonstrate leucine supplementation improves 
glycemia in mice [195]. 
          Mechanistically, part of these leucine-induced positive metabolic effects, such as 
reduced body fat, increased glucose tolerance and insulin sensitivity, are the consequence 
of decreased food intake. Leucine has been found to activate mTOR signaling and inhibit 
AMPK in the hypothalamus, leading to inhibition of food intake, known as anorectic 
effect [192]. In addition, leucine has been found to decrease adiposity and improve 
insulin sensitivity in HFD-fed mice via promoting thermogeneiss by increaseing UCP3 
expression in brown adipose tissue [193]. 
         Leucine may also protect agaisnt HFD-induced abnormalities directly in peripheral 
tissues, such as adipose tissue and skeletal muscle, without changing food intake or 
bodyweight. For example, Macotela et al. found leucine to resuce HFD-induced 
metabolic abnormalities withouth chaning weight gains compared to controls [190]. 
Interestingly, althought they found leucine triggered activation of mTOR signaling and 
IRS phosphorylation, which is normally considered as an insulin resistance phenomenon, 
leucine intake attenuated HFD-induced metabolic abnormalities, suggesting that other 
mechanisms might be invovled in leucine’s positive effect, such as AMPK and SIRT1 
signaling. 
          According to Saha et al. excess leucine intake downregulates the fule sensing and 
singling enzyme AMPK, which subseuqnelty activates mTOR-p70S6K, resulting in 
insulin resistance [194]. In contrast, recent data demonstrate that leucine and its 
metabolites (HMB) activate AMPK synergistically with resveratrol and metformin, 
resulting in increased insulin sensitivity in 3T3L1 adipocytes and diet-induced obese 
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mice [195, 196]. Consistent with this, Roger et al. found that leucine markedly enhanced 
oxidative capacity and increased mitochondrial density in skeletal muscle, in part, 
through AMPK-mediated increases of PGC-1α [197]. 
           SIRT1 activation also appears to contribute to the leucine’s beneficial metabolic 
effects. Macotela et al. found that leucine rescued SIRT1 expression and intracellular 
NAD+ level back to normal levels in liver and muscle, associated with improved insulin 
sensitivity in HFD mice [190]. Li et al. reported that leucine supplementation not only 
increased SIRT1 expression and activity, but also prevented mitochondrial dysfunction, 
accompanied by decreased acetylation of PGC-1α and FOXO1[198]. Similar data have 
been found in our previous studies. Leucine stimulates mitochondrial biogenesis and 
oxygen consumption in both C2C12 myotubes and 3T3L1 adipocytes through a SIRT1-
dependent pathway [199]. Consistently, high dairy (rich in leucine) intake significantly 
decreases oxidative and inflammatory stress level in overweight and obese subjects in 
human, associated with activation of SIRT1 [13].  
 However, the mechanisms underlying leucine activation of AMPK and SIRT1 are 
still unknown. According to our recent data, leucine and its metabolites (HMB and KIC) 
have been found to increase recombinant human SIRT1 enzyme activity by 30 to 100% 
via direct allosteric conformation in cell free system, which reduces over 50% of SIRT1 
Km values to NAD+ and substrate [196]. Recent evidences from Basil’s study [200] 
indicate that specific hydrophobic motif in SIRT1 substrates and a single amino acid 
(Glu230) in SIRT1 N-terminal domain facilitate the activation of SIRT1 enzyme by 
STACs [200]. For example, fluorophores are bulky and hydrophobic, and have been 
found to activate SIRT1 in vitro with resveratrol [201].  
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Figure 2-7: Model of allosteric activation of SIRT1 by sirtuin activating compounds 
(STACs).  
(A) SIRT1 acting on a substrate with a hydrophobic signature (yellow) in the absence of 
a STAC. (B) Binding of a STAC alters the N-terminal structure of SIRT1 but the absence 
of hydrophobic residues C-terminal to the acetyl-lysine on the substrate prevents 
activation by STACs. (C) The aminomethycoumarin group on the Fluor-de-Lys peptide 
substrate mimics hydrophobic residues of natural substrates, facilitating activation by 
STACs. (D) Substrate contains hydrophobic residues C-terminal to the acetyl-lysine thus 
allowing STAC-induced activation. Mutation of E230 allows STACs to bind to SIRT1 but 
abolishes STAC-mediated allosteric activation. Adopted from Kugel S et al., 2013 [202] 
 
          Leucine is a highly hydrophobic amino acid, which might also explain the direct 
activation effect [202]. Indeed, with the presence of leucine and HMB, lower 
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concentrations of resveratrol are required for the activation of SIRT1 and AMPK, as well 
as increases in insulin sensitivity and glucose uptake in both in vivo and in vitro studies 
[130]. 
 2.5.5   Tissue-, dose- and time- dependent manners of leucine 
          The impacts of leucine on energy metabolism are so different among the studies 
that may reflect a time-dependent manner. For instance, short-term leucine administration 
promotes insulin resistance, accompanied by increased phosphorylation of mTOR, JNK 
and IRS1 in HFD-fed rat [11]. While, a chronic high BCAAs diet leads to improved 
insulin sensitivity in patients with liver diseases [203].  
           Leucine has been found to promote energy partitioning from adipocytes to muscle 
cells under co-culture condition, resulting in decreased lipid accumulation in adipocytes 
and increasing fatty acid oxidation in muscle [204]. In obese subjects, specialized whey 
fraction (rich in leucine) significantly reduced 6.1% of the body fat mass and promoted 
higher protein synthesis in muscle compared to the lean controls [205]. Moreover, leucine 
protects against HFD-induced insulin resistance and decreases inflammatory stress in 
perigonadal (PG) fat by blocking macrophage infiltration and inflammatory marker genes 
expression, despite leucine having no effect on weight loss of intra-abdominal/PG or 
adipocytes sizes [190]. Indeed, dietary leucine has been found to inhibit expression of 
NFκB, a transcription factor triggering wide range of genes involved in inflammation, 
resulting in significant decreases of oxidative and inflammatory stress, partially via 
activation of mTOR signaling [13]. Furthermore, leucine supplementation is able to 
improve insulin secretion synergistically with glucose in β-cells, leading to the 
improvement of whole body glucose tolerance, without changing the body weight [206]. 
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Previous studies demonstrate that activated SIRT1 promotes insulin secretion in 
pancreatic β-cells [207], and leucine is a potential SIRT1 activator, therefore, leucine 
might be able to promote insulin sensitivity by stimulation of insulin release in a SIRT1-
dependent pathway in pancreatic endocrine cells. 
          In addition to tissue-specific impacts, leucine might modulate energy metabolism 
associated with the dose of the leucine intake and the metabolic status of the subjects. For 
example, Leucine primarily serves as a substrate for new protein synthesis at 1-4 g/d 
intake, and then as precursors for alanine and glutamine production after meeting the 
minimum needs. When the intake reaches up to 7~12 g/d, leucine exhibits regulatory 
impacts on energy metabolism, such as improving skeletal muscle glucose uptake and 
utilization, reducing food intake and body weight through activation of mTOR signaling 
in hypothalamus [160]. Zhang et al. [191] and Opara et al [208] consistently found that 
leucine improved glucose tolerance and insulin sensitivity in HFD-fed mice, but not in 
chow diet-fed mice. Nairizi et al. confirmed these data by showing that leucine improved 
glycaemia in HFD-fed mice, although either higher level of leucine (150 mm/l) or 
BCAAs (109 mm/l) could not rescue the diet-induced obesity [209]. Meanwhile, modest 
increases in leucine intake, sufficient to raise plasma leucine to ~ 0.5mm/l, significantly 
reduced obesity-related oxidative and inflammatory stress, resulting in improvement of 
insulin sensitivity in humans [204]. Similarly, Roger et al. found that leucine in the 
0.1mm/l – 0.5mm/l range induces a dose-dependent expression of PGC-1α, leading to 
significant increases of mitochondrial density and oxidative capacity in skeletal muscle 
cells [197]. 
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Part Three 
Leucine Modulates Mitochondrial Biogenesis and 
SIRT1-AMPK Signaling in C2C12 Myotubes 
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3.1   Abstract 
Background: 
SIRT1 (Silent Information Regulator Transcript 1) and AMPK (AMP-activated protein 
kinase) are important regulators of energy metabolism, and the activation of both 
enzymes have been reported to prevent the development of insulin resistance and type 2 
diabetes. We have shown that leucine stimulates Sirt1 gene expression as well as 
mitochondrial biogenesis in vivo and in vitro. In addition, β-hydroxy-β-methyl butyrate 
(HMB), a metabolite of leucine, has been reported to activate AMPK synergistically with 
resveratrol in C2C12 myotubes. Accordingly, we sought to determine the roles of SIRT1 
and AMPK in leucine-stimulated mitochondrial biogenesis in C2C12 well differentiated 
myotubes. 
Methods: C2C12 myotubes were treated with leucine (0.5 mM), alanine (0.5 mM), 
valine (0.5 mM), EX527 (SIRT1 inhibitor, 25 µM) and Compound C (AMPK inhibitor, 
25 µM) alone or in combinations for various lengths of time as indicated in figure 
legends.  
Results: Mitochondrial content, the expression levels of genes involved in mitochondrial 
biogenesis, fatty acid oxidation, SIRT1 activity and gene expression, and AMPK 
phosphorylation in C2C12 myotubes were significantly increased by the leucine 
treatment compared to the controls, and these effects were markedly attenuated by 
EX527 and Compound C. Further, leucine treatment for 24-hours resulted in time-
dependent increases in NAD+ level, SIRT1 activity and p-AMPK level. Although both 
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SIRT1 and AMPK activation were essential for leucine-stimulated mitochondrial 
biogenesis, leucine activates SIRT1 ahead of AMPK. 
Conclusion: These results indicate that leucine promotes mitochondrial biogenesis in a 
SIRT1 and AMPK dependent manner in C2C12 myotubes, with SIRT1 activation being 
the primary event. 
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3.2   Introduction 
Caloric restriction (CR) has been shown to extend life span and delay the onset of 
aging-associated pathology in many species, such as yeast, worms, flies and some 
mammals [1]. These beneficial effects of CR are mediated partially through activation of 
Sir2 (Silent Information Regulator Two) in lower species and its orthologue SIRT1 in 
mammals. By sensing cellular energy status via intracellular NAD+/NADH 
(Nicotinamide adenine dinucleotide) ratio, SIRT1 regulates target genes expression by 
changing acetylation status of histone and transcriptional factors, such as peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), tumor suppressor 
p53 (p53), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
Forkhead box O3 (FOXO3) [2], resulting in modulation of wide range of cellular 
fundamental processes, including DNA repair, metabolic regulation, and cell apoptosis 
[3, 4]. Overexpression of SIRT1 protects against high-fat diet (HFD)-induced metabolic 
abnormalities, such as insulin resistance, glucose intolerance and liver steatosis; without 
extending their lifespan in mouse models [5]. In addition, activated SIRT1 deacetylates 
and activates PGC-1α, a major regulator of mitochondrial biogenesis and metabolism, 
leading to improvement of insulin sensitivity and decreases of oxidative and 
inflammatory stress [6]. Therefore, small molecules that could activate SIRT1 and mimic 
the CR-induced positive effects have drawn considerable attention.  
Leucine, a branched-chain amino acid, stimulates tissue protein synthesis through 
both mTOR-dependent and independent pathways[7] [8]. However, leucine appears to 
play a distinct role in energy metabolism in addition to its pivotal function in protein 
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synthesis. For example, studies have shown that leucine administration promotes energy 
partitioning from adipocytes to muscle cells, leading to decreased lipid storage in 
adipocytes and increased fat utilization in muscle [9]. Also, leucine supplementation 
increases insulin sensitivity and glucose tolerance by promoting glucose uptake and fatty 
acid oxidation in skeletal muscle in HFD mice [10-13]. In fact, evidences suggest that 
these leucine-induced beneficial metabolic effects are mediated partially through SIRT1 
activation, as Sirt1 knockout significantly diminishes these changes [14, 15]. Consistent 
with this, our recent data indicate that leucine directly activates SIRT1, and promotes the 
enzyme affinity for NAD+[14], leading to increased fatty acid oxidation in adipocytes and 
myotubes [16, 17];  
Further, leucine promotes AMPK (AMP-activated protein kinase) 
phosphorylation synergistically with metformin; resulting in significant increases in 
insulin sensitivity and glucose tolerance in mice [18]. AMPK is an evolutionary 
conserved enzyme and serves as an energy status sensor in eukaryotes [19]. Similar to 
SIRT1, AMPK is activated and phosphorylated in response to energy restriction. 
Increased cellular AMP or AMP/ATP ratio activates AMPK through LKB1 (kinases 
tumor suppressor liver kinase B1) and Camkkβ (Ca2+/calmodulin-dependent kinase 
kinase beta) signaling pathways, and subsequently promotes a cell catabolic shift with 
increased fatty acid oxidation and ATP production to rescue the energy crisis [20]. In 
fact, data from resveratrol (a SIRT1 activator) studies have shown that SIRT1 activation 
in vivo is highly associated with phosphorylation of AMPK [1, 21]. All these evidences 
provide a framework of leucine’s modulation mechanism on SIRT1 and AMPK in 
skeletal muscle [17, 22].  
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Since SIRT1 and AMPK share multiple metabolic substrates [23], and part of the 
two enzymes signaling pathways are overlapped, we hypothesize that leucine-induced 
activations of SIRT1 and AMPK are the major events that regulate fatty acid oxidation 
and mitochondrial biogenesis in skeletal muscle cells.  
Accordingly, we examined the effects of leucine, valine (branched-chain amino 
acid control), and alanine (non-branched chain amino acid control) on mitochondrial 
biogenesis, SIRT1 activation, and phosphorylation of AMPK in C2C12 myotubes. In 
addition, we also used EX-527 (SIRT1 selective inhibitor) and Compound C (specific 
AMPK inhibitor) to probe the role of each enzyme in leucine modulation of energy 
metabolism in differentiated C2C12 myotubes. 
3.3   Materials and Methods 
3.3.1   Cell Culture 
C2C12 myoblast cells were seeded at a density of 1.2×106 cells per well in 6-well 
plates and incubated in Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5g/L 
D-glucose, 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C and 
5% CO2. After the cells reach 90% confluence, the medium was switched to a standard 
differentiation medium (DMEM supplemented with 2% Horse Serum and 1% antibiotics) 
for 2 to 4 days. The differentiation media was changed every other day to allow 90% 
cells to form myotubes (3-5 days later) before additional treatments began.  
The dosages of reagents were 0.5mM for leucine, 0.5mM for alanine, 0.5mM for 
valine, 100nM for Resveratrol, 20µM for EX527, 20µM for Compound C, and 50µM for 
AICAR. The incubation lengths were from 1 to 48 hours as indicated in the figure legend. 
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3.3.2.   Measurement of mitochondrial biogenesis related genes 
expression 
           Total RNA was extracted from C2C12 cells using Ambion ToTally RNA Isolation 
Kit (Ambion, Inc., Austin, TX, USA) according to the manufacture’s instructions. Total 
RNA content was determined using NanoDrop ND-1000 Spectrophotoeter (NanoDrop 
Technologies Inc., Wilmington, DE, USA). RNA quality was assessed by the 
260nm/280nm ratio (1.8-2.0) and 260nm/230nm ratio (2.0). The expression levels of 
myotube ribosomal 18S (18S), Sirt1, Sirt3, PGC-1α, cytochrome c oxidase subunit 5b 
(Cox5b), heat shock cognate protein 1 (Hspd 1) and Cox2 genes were measured via 
quantitative real-time PCR using TaqMan Universal PCR Master Mix kit (Applied 
Biosystems, Branchburg, NJ, USA) according to the manufacturer’s instructions. The 
real-time PCR reactions were carried out in 96-well format using ABI 7300HT 
instrument, with cycle condition of 48°C 30min, then 40 cycles of 95°C for 15s/60°C for 
1 minute. The mRNA levels were normalized against endogenous housekeeping gene 18S 
with standard curve. Data for each gene was presented as a ratio to 18S. 
3.3.3   Measurement of SIRT1 enzyme activity 
SIRT1 Fluorometric Drug Discovery Kit (BML-AK555, ENZO Life Science 
International, Inc. PA, USA) was used to measure SIRT1 activity in C2C12 cells, 
following the manufacturer instruction. In this assay, SIRT1 activity was determined by 
deacetylation reaction of a standardized substrate that contains an acetylated lysine 
residue. This Fluor de Lys® substrate is a peptide containing amino acids 379-382 of 
human p53 (Arg-His-Lys-Lys(Ac)), serving as a direct target for SIRT1. SIRT1 activity 
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is proportionally related to the degree of deacetylation of Lys-382 and the corresponding 
fluorescence signal changes.  
All the cell lysates were harvested by homogenizing cells in RIPA buffer, which 
contains protease inhibitor cocktail (MP Biomedicals LLC, Solon, OH, USA) (100: 1 
v/v). After 5 seconds ultrasonication on ice, the cell lysates were centrifuged at 12,000 × 
g for 5 minutes. The supernatants were used for SIRT1 activity assessment and other 
experiments. According to the protocol, 5 µl of cell lysate were used for the endogenous 
SIRT1 activity detection. Samples were incubated in a PBS (phosphate-buffered saline) 
solution with peptide substrate (25 µM) and NAD+ (500  µM) at 37°C on a horizontal 
shaker for 45 minutes. The deacetylation reaction was stopped with the addition of the 
stop solution (2mM nicotinamide) and developer that binds to the deacetylated lysine to 
form a fluorophore. Following 10 minutes of incubation at 37°C, fluorescence intensity 
was determined using a Glomax Multi Detection system (Promega, WI, USA), with 
excitation and emission wavelengths of 360 nm and 450 nm, respectively. Resveratrol 
(100 mM) and suramin sodium (25 mM) were used as positive and negative controls, 
respectively. To normalize the data of SIRT1 activity, concentrations of the sample 
cellular protein were measured using BCA-assay. 
3.3.4    Measurement of fatty acid oxidation  
Cellular fatty acid oxidation was measured using [3H]-palmitate, as described in 
our previous studies [9]. C2C12 cells in 12-well plates were washed with 2 ml of cold 
PBS solution twice and incubated in 1 ml of Hank’s basic salt solution containing 
0.5mg/ml BSA, 22 µM-unlabeled palmitate plus 5 µM [3H]-palmitate (32.4 mCi/µm) for 
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2 hour. All of the reaction solutions were collected from each well, and then 200 µl of 
10% trichloracetic acid and 6 N NaOH were added in the solution. Mixtures were then 
removed from each well and placed in corresponding poly-prep chromatography columns 
with 1.5 ml Dowex-1 overnight. The 3H2O passed through the column was collected into 
a scintillation vial, and radioactivity was measured with a liquid scintillation counter. The 
protein level of each well was measured using BCA reagent and used to normalize the 
palmitate oxidation data. 
3.3.5    Western Blotting 
Primary antibodies for total AMPKα (AMP-activated protein kinaseα), p-
AMPKα (Phosphor-AMPKα), ACC (Acetyl-CoA Carboxylase), and p-ACC (Phospho-
ACC) were obtained from Cell Signaling Technology Inc (Danvers, MA, USA). And 
Horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody was 
obtained from Thermo Scientific Inc (Waltham, MA, USA).  
Following the indicated treatments, C2C12 myotubes were washed twice with ice 
cold PBS, and the total cell lysates were prepared using RIPA buffer plus 
protease/phosphatase inhibitor cocktails with 100:1:1 (v/v/v, ratio) (Sigma-Aldrich). 
Following a 10-minute centrifugation at 14,000 x g, the supernatants were collected for 
the determination of protein content using BCA assay kit (Thermo Scientific Inc, 
Waltham, MA, USA) and western blotting. Equal amount of total cell lysates (20 µg) 
were loaded to 10% SDS-PAGE (10 cm x 10 cm, Criterion precast gel, Bio-Rad 
Laboratories, Hercules, CA, USA) and transferred to PVDF membrane (polyvinylidene 
difluoride membrane) (Bio-Rad, Hercules, CA). The membrane was incubated in 25 ml 
blocking buffer (1× TBS, 0.1% Tween-20 with 5% w/v nonfat dry milk) for 1 hour at 
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room temperature. Then the membrane was incubated in TBST containing 5% dry milk 
with primary antibody (1:1000) with gentle agitation at 4°C overnight, washed three 
times with TBST and incubated with TBST containing rabbit HRP-conjugated secondary 
antibody (1:5000) for 1 hour at RT. Bound antibodies were visualized by 
chemiluminescence (ECL Western Blotting Substrate, Thermo Scientific) and 
membranes were exposed to X-ray films (Phenix Research Product, Candler, NC) for 
protein band detection. The films were scanned using an HP Scanjet 39070 (Palo Alto, 
CA 94304) and stored as Tagged Image File Format (TIFF) at 300dpi. The protein bands 
were quantified by densitometry using BioRad ChemiDoc instrumentation and software 
of Image Lab 4.0 (Bio-Rad Labratories).  
3.3.6    Measurement of mitochondrial contents  
Mitochondrial abundance in C2C12 myotubes was assessed by 10-N-nonyl 
acridine orange (NAO) dye (Life Sciences, PA, USA) according to manufacturer’s 
instruction. After desired treatment, cells in 96-well plates were treated with 10 µμl NAO 
dye in each well, following 2-hour incubation at 37°C in the dark. NAO itself is not 
fluorescent, but it can be oxidized into the fluorescent-NAO by oxidative species, and 
accumulated in mitochondrial membranes. The absorbance in each well was measured at 
570 nm wavelengths (Promega, WI, USA), and normalized with cellular protein level. 
The image of mitochondria was taken using a Nikon Eclipse Ti-E Ti-E Fluorescence 
microscope (Nikon Metrology, Inc. US) equipped with an automated stage and a 20 X 
objective. A 3 × 3 large image scan was taken in each of 5 random fields by multi-
channel capture (channel 1: excitation/emission= 488/517, channel 2: excitation/emission 
= 550/567 nm). 
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3.3.7    Statistical analysis 
Data presented as means ± standard deviation (SD). Levene's test was used to 
determined homogeneity of variance among groups using SPSS 21.0 statistical software 
(IBM, Armonk, NY) and where necessary natural log transformation was performed 
before analysis. Multiple comparisons were analyzed by one-way analysis of variance 
(ANOVA) using least significant different when equal variance was assumed, and 
Games-Howell test was used when equal variance was not assumed. The independent 
sample t-test was used to compare two conditions. Differences were considered 
statistically significant at P < 0.05.   
3.4    Results 
3.4.1   Leucine treatment induced the mitochondrial biogenesis in 
C2C12 myotubes  
Figure 3-1 shows the changes of mitochondrial content (A), expression level of 
mitochondrial biogenesis genes (B), SIRT1 enzyme activity (C) and fatty acid oxidation 
(D) in C2C12 myotubes treated with vehicle control, leucine, valine and alanine for 48 
hours. Leucine significantly increased mitochondria content in C2C12s compared to 
alanine and valine (p=0.007) (Fig. 3-1A). These effects were accompanied by increases 
in mRNA expression levels of PGC-1α (198%, p=0.01) and SIRT3 (167%, p=0.03) with 
leucine treatment (Fig. 3-1B). Moreover, SIRT1 activity (p=0.017) and fatty acid 
oxidation (p=0.03) in the C2C12s were highly elevated by leucine compared to the 
control groups (Fig. 3-1C and D, respectively).  
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Figure 3-1: Leucine treatment induces mitochondrial biogenesis and SIRT1 
enzymatic activity in C2C12 myotubes  
Mitochondrial contents were quantitated with NAO dye (10 µM) (A) 48 hours after treated 
the cells treated with leucine (0.5 mM), alanine (0.5 mM) and valine (0.5 mM); mRNA 
expression levels of PGC-1α and SIRT3 (B) with the same treatments were evaluated by 
quantitative RT-PCR. The relative mRNA expression was normalized to 18S and 
expressed as dark and grey bars. Cellular SIRT1 activity (C) and palmitate oxidation 
ability (D) were measured after leucine and its amino acids controls, and the results 
were normalized to cellular protein level for each sample. Data are mean ± SE (n=4). 
Different letters indicate significant differences between solid or gray bars. * Significantly 
different from controls with p<0.05. 
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3.4.2   SIRT1 is required for leucine–induced mitochondria biogenesis in 
C2C12 myotubes 
We used a selective SIRT1 inhibitor, EX527, to determine the role of SIRT1 in 
leucine-induced mitochondrial biogenesis. Leucine increased mitochondrial biogenesis as 
demonstrated by significant increases in mitochondrial content (p=0.001), palmitate 
oxidation (p=0.038) and mitochondrial biogenesis-related gene markers PGC-1α 
(p=0.003), SIRT3 (p=0.031) and COX5b (p=0.015) (Fig. 2 A, C-D, dark panel), and these 
effects were markedly attenuated by EX527 administration (Fig. 3-2 A, C-D, grey panel). 
Comparing the relative SIRT1 expression, leucine and resveratrol (positive control) 
markedly increased Sirt1 mRNA level (p=0.020); paradoxically, the SIRT1 inhibitor 
(EX527) (p=0.015) revealed the same pattern (Fig.3-2 B). 
3.4.3   Leucine induces phosphorylation of AMPK in a SIRT1-
dependent manner 
            We found that 6-hour treatment of leucine resulted in 3-fold increase in AMPK 
phosphorylation in the C2C12 myotubes, which was significantly different from baseline, 
valine and alanine. Consistent with this observation, phosphorylation of Acetyl-CoA 
carboxylase (ACC), a downstream target of AMPK, was also elevated by leucine 
treatment compared to the controls (p=0.014) (Fig. 3-3 A), while EX527 supplementation 
resulted in corresponding suppression of AMPK phosphorylation (p=0.012)(Fig. 3-3 B), 
indicating the requirement of SIRT1 for leucine-induced AMPK activation.  
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Figure 3-2: Leucine improves Mitochondrial biogenesis in C2C12s in a SIRT1- 
dependent Manner  
(A) Mitochondrial contents and imagines were detected using NAO (10 µM) dye after 48-
hour leucine, leucine plus SIRT1 inhibitor (EX527 25 µM) treatments in C2C12 cells. (B, 
C) SIRT1 activity and mitochondrial biogenesis related gene (PGC-1α, SIRT3, COX5b) 
mRNA levels were measured after the same treatments.  The relative SIRT1 activity was 
normalized to cellular protein level, and mRNA was normalized to housekeeper gene 
18S. (D) palmitate oxidation level was detected after the same treatment, and the results 
were normalized to cellular protein for each sample.  Data are mean ± SE (n=4). 
Different letters indicate significant differences between solid or gray bars. * Significantly 
different from controls, and ** significantly different from control and EX527 groups with 
p<0.05. 
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Figure 3-3: Leucine induces phosphorylation of AMPK and ACC in SIRT1-
dependent manner in C2C12 Myotubes 
(A) C2C12 myotubes were serum starved overnight and treated with leucine (0.5 mM), 
alanine (0.5 mM), valine (0.5 mM), DMSO for 6 hour. The whole cell lysate was prepared 
with RIPA buffer plus protease/phosphatase inhibitor cocktails with 100:1:1 (v/v/v, ratio) 
The cell lysates were detected by western blotting analysis with specific antibodies 
against phosphor-AMPKα, phosphor-ACC, total AMPKα (Thr 172) and beta-actin. 
Integrated density values for the p-AMPK and p-ACC was normalized to total-AMPK 
band density and represented as dark or gray bars. (B) C2C12 cells were treated with 
0.2% FBS medium overnight and then treated with leucine (0.5 mM), Resveratrol (100 
nM) and leucine plus EX527 (25 uM) for 6 hour. Integrated density value for phosphor-
AMPK was normalized to total-AMPK. * Significantly different from controls with p<0.05. 
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3.4.4   Leucine stimulates SIRT1 activity, phosphorylation of AMPK 
and cellular NAD+ in a time-dependent manner.  
To determine the interplay between SIRT1 and AMPK, we measured the cellular 
NAD+ level, SIRT1 activity, and phosphorylation level of AMPK at 0, 1, 4, 6, 12 and 24-
hours by leucine administration in C2C12 myotubes. Leucine increased SIRT1 activity at 
1 (p=0.028), 12 (p=0.042) and 24 hours (p=0.010) compared to the baseline (Fig.3-4 A). 
However, no change was observed for cellular NAD+ content and p-AMPK level during 
the first 4 hours. NAD+ level was elevated almost two-fold higher at time point 4- 
(p=0.025) and 24-hour (p=0.010) compared to baseline level, and otherwise remained 
low (Fig. 3-4 B); The levels of p-AMPK was markedly increased and stayed high from 4- 
to 24-hours (p=0.000) (Fig. 3-4 C). 
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Figure 3-4: Leucine activates SIRT1 activity, AMPK phosphorylation and cellular 
NAD+ level in a Time-dependent manner  
C2C12 myotubes were serum starved overnight and treated with Leucine (0.5 mM). Cell 
lysate was collected and analyzed for cellular SIRT1 activity; western blotting of p-AMPK 
and cellular NAD+ levels at indicated certain time points. (A) SIRT1 activity was activated 
at 1, 12 and 24 hours after leucine treatment. (B) Cellular NAD+ level showed similar 
pattern as SIRT1 activity at time points 4 and 24. Both SIRT1 activity and NAD+ level 
were normalized to cellular protein for each sample. (C) Phosphorylation level of AMPK 
was detected using western blotting following the same time course in C2C12 cells, 
resveratrol serving as positive control. Data are mean ± SE (n=3). * Significantly different 
from point 0, and ** significantly different from time point 1.  
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3.4.5   Leucine-induced mitochondrial biogenesis in C2C12 myotubes 
requires AMPK 
We next examined whether AMPK also mediates leucine’s modulation on 
mitochondrial biogenesis in C2C12 myotubes. As shown in Figure 3-5, leucine treatment 
markedly increased the mRNA expression levels of mitochondrial component genes (Fig. 
3-5A, dark columns), Hspd1 (p=0.003) and COX2 (p=0.003). Similar effects were found 
for mitochondrial biogenesis-related genes, PGC-1α (p=0.001), Sirt1 (p=0.022) and 
Cox5b (p=0.04), (Fig. 3-5B, Dark columns). Compound C treatment markedly impaired 
all these inductions (Fig. 3-5 Grey panels). 
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Figure 3-5: AMPK inhibitor attenuates leucine-induced mitochondrial biogenesis  
(A, B) C2C12 myotubes were treated with leucine (0.5 mM), AICAR (20 µM) and 
Compound C (25 µM) for 24 hour. mtDNA levels of the cells were analyzed by the gene 
expression levels of mitochondrial markers, Hspd1 and COX2 using real-time PCR. (C, 
D) Mitochondrial biogenesis related gene mRNA expression of PGC-1α and COX5b 
were evaluated also by RT-PCR. (E) SIRT1 gene expression after leucine and 
Compound C administration were measured; all the mRNA levels were normalized to 
18s housekeeping gene. Data are mean ± SE (n=4). Different letters indicate significant 
differences between solid or gray bars. * Significantly different from controls.  
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3.5    Discussion 
These data indicate that leucine stimulates significant muscular metabolic 
changes, including SIRT1 activation, AMPK phosphorylation and mitochondrial 
biogenesis in C2C12 myotubes. These changes may contribute to leucine’s beneficial 
effects on energy metabolism and insulin sensitivity in both animal and human models 
[13, 15, 24, 25]. 
Previous clinical trial data have shown that high dairy intake (rich in BCAAs) 
induced significant suppression of ROS and inflammatory stress, indicated by decreased 
plasma tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) and monocyte 
chemoattractant protein-1 (MCP-1) levels [15]. Doubling leucine intake in mice has been 
found to reverse multiple HFD-induced metabolic abnormalities, including glucose 
intolerance, hepatic steatosis and inflammation [7]. These effects are accompanied by 
corresponding increases in mitochondrial function and biogenesis. Impairment of 
mitochondrial oxidative function or decreases in mitochondrial mass are directly linked 
to the development of metabolic disorders [26], such as insulin resistance, type 2 
diabetes, age-related hearing loss and some types of cancers [27], while, increased 
mitochondrial function and mitochondrial biogenesis appears to rescue obese-related 
metabolic abnormal [28]. Our previous studies indicate that leucine promotes 
mitochondrial biogenesis in both adipocytes and myotubes, and leads to energy 
partitioning from adipocytes to muscle cells, resulting in decreased energy storage in 
adipocytes and increasing fat utilization in muscle [9]. 
Here, we show that 0.5 mM leucine treatment, which is comparable to the plasma 
leucine concentration achieved by a leucine-rich diet, such as a high dairy diet [29], can 
83	  	  	  
have significant impacts on mitochondrial biogenesis and oxidative function in C2C12 
myotubes. Compared to other BCAA control (valine) and non-branched-chain amino acid 
control (alanine), leucine markedly increases mitochondrial content and fatty acid 
oxidation.  
The data herein demonstrate that the improvement of fatty acid oxidation and 
mitochondrial content by leucine is accompanied by increased SIRT1 activity in C2C12 
cells. SIRT1, a NAD+-dependent deacetylase, has been demonstrated to play significant 
roles in leucine-induced beneficial effects on energy metabolism. In Yazmin et al. ’s 
study [7], leucine restores HFD-reduced hepatic NAD+ and SIRT1 expression back to 
normal levels. Similarly, Li et al. demonstrate that leucine increases SIRT1 expression 
and deacetylation level of PGC-1α, resulting in attenuation of HFD-induced 
mitochondrial dysfunction, insulin resistance and obesity in mice [30]. Similarly, Sun and 
Zemel found that leucine induces mitochondrial biogenesis in muscle cells by stimulating 
expression of PGC-1α and NRF-1 via a SIRT1-dependent pathway [22]. These findings, 
along with the observations reported here, are in agreement with our recent work that 
leucine could activate SIRT1 enzyme through allosteric interaction in adipocytes and 
myotubes [23]. 
SIRT1 has been reported to directly activate and deacetylate PGC-1α during 
caloric restriction, leading to increased mitochondrial metabolism to maintain cellular 
energy balance[31]. SIRT3, a mitochondrial sirtuin, serves as downstream target of PGC-
1 α via estrogen-related receptor alpha (ERRα), and may also contribute to mitochondrial 
biogenesis by suppression of ROS production [32]. Consistent with leucine’s effect on 
SIRT1 and PGC-1 α, SIRT3 expression was also elevated in C2C12 myotubes by leucine. 
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To establish whether or not SIRT1 is required for leucine-induced mitochondrial 
biogenesis, EX527 (specific SIRT1 inhibitor) was used to treat the cells in combination 
with leucine. EX527 significantly attenuated leucine-induced mitochondrial content, 
mitochondrial biogenesis-related genes expression and fatty acid oxidation in C2C12 
myotubes. The observations reported here are consistent with Price et al., who found that 
SIRT1 knockout can completely block resveratrol-promoted mitochondrial biogenesis 
and function in skeletal muscle [33], further supporting the essential roles of SIRT1. 
Paradoxically, SIRT1 gene expression level was also increased by EX527, although the 
mechanism of that effect is not clear.  
We also found that AMPK phosphorylation, which is elevated in response to 
metabolic energy stress [34], was also increased by leucine treatment. This change might 
help explain leucine-induced improvement in fatty acid oxidation in the cells. Similarly, 
in mice, leucine supplementation has shown to activate AMPK synergistically with 
resveratrol and metformin, leading to increases of insulin sensitivity and glucose 
tolerance [18]. On the other hand, Compound C, an inhibitor of AMPK, markedly 
blocked leucine’s effects on mitochondrial biogenesis, indicating that like SIRT1, AMPK 
is also required for leucine to promote mitochondrial biogenesis and fatty acid oxidation 
in C2C12 myotubes. 
Notably, we found that leucine-induced AMPK phosphorylation was highly 
decreased by SIRT1 inhibitor (EX527), suggesting that AMPK might serve as a 
downstream target of SIRT1. Park et al. found that resveratrol activates SIRT1 via an 
indirect pathway involved in activation of Camkkβ -AMPK. Price et al. reported that 
SIRT1 activation is required for AMPK phosphorylation and improvement of 
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mitochondrial function via deacetylation and activation of LKB1 both in vivo and in vitro 
[33, 35]. Currently available evidence suggests that AMPK and SIRT1 display a mutual 
interaction with each other; AMPK activates SIRT1 by increasing cellular NAD+ level 
through promoting expression of Nicotinamide phosphoribosyltransferase (Nampt), a 
rate-limiting enzyme in NAD+ biosynthesis. Meanwhile, SIRT1 directly deacetylates and 
activates LKB1, an key upstream kinase of AMPK, leading to the modulation AMPK 
activity [36].  
Our time-course data suggest that SIRT1 may be the initial target of leucine. 
SIRT1 activity was increased within the first hour of leucine treatment, while cellular 
NAD+ and p-AMPK levels remained unchanged. Considering the increased Sirt1 gene 
expression and SIRT1 activity level occurred at some time after the leucine treatment for 
24 hours, it is possible that both SIRT1 activity and expression are elevated by leucine 
first, and then activation of AMPK is a subsequent event.  
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Figure 3-6: Proposed mechanism of leucine-induced mitochondrial biogenesis 
In C2C12 myotubes, leucine treatment leads to activation of SIRT1, perhaps by direct 
allosteric interaction. SIRT1 then deacetylates and activates LKB1, which subsequently 
induces AMPK phosphorylation and activation. In turn, activated AMPK could promote 
SIRT1 activation via intracellular NAD+ level by changing expression and activity of 
Nampt. The corporate activation of AMPK and SIRT1 further activates PGC-1a via 
phosphorylation and deacetylation, resulting in elevated mitochondrial biogenesis and 
oxidative function. 
 
         Our data may reflect dose-dependent effects of leucine treatment. For example, in 
contrast to our findings, high-dose leucine infusion (total plasma leucine approximately 2 
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mm/l) has been shown to produce insulin resistance and glucose intolerance in humans 
[37]. Similarly, short-term BCAAs supplementation with HFD in rats also increases 
insulin resistance compared to HFD alone [38], possibly due to activation of mTOR 
signaling. Leucine activates mTOR signaling and leads to activation of p70 ribosomal S6 
kinase (p70S6K), which subsequently phosphorylates serine/threonine residues of insulin 
receptor substrate 1 (IRS1), resulting in suppression and degradation of IRS-1 and the 
impairment of insulin signaling [39]; In contrast, modest increases in leucine intake, 
sufficient to induce plasma leucine elevations to ~ 0.5mm/l, significantly reduced 
obesity-related oxidative and inflammatory stress, resulting in improvement of insulin 
sensitivity in humans [15]. Similarly, Roger et al. found that leucine in the 0.1mm/l – 
0.5mm/l range induces a dose-dependent increases of PGC-1α expression, leading to 
significant elevated mitochondrial density and oxidative capacity in skeletal muscle cells 
[13]. Consistent with this, we found comparable levels of leucine promoted 
mitochondrial biogenesis and fatty acid oxidation in C2C12 myotubes. 
There are several limitations to this study. One of them is the use of the Fleur de 
Lys assay to measure SIRT1 activity. Studies have challenged the validity of the assay, as 
some studies have found that sirtuin-activating compounds (STACs) only increased 
SIRT1 activity by using fluorophore-tagged substrates but not the matching non-tagged 
peptides, which also might explain why this SIRT1 activation can be found exclusively in 
vitro but not in vivo [40, 41]. Moreover, according to Borra et al, the fluorophore acts 
synergistically with STACs to promote binding between substrate and SIRT1 enzyme 
protein [42]. Furthermore, evidence suggests resveratrol-induced SIRT1 activation is 
actually mediated through an indirect signaling pathway involved in cAMP 
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phosphodiesterases (PDE) and AMPK in vivo [35]. However, Hubbard et al. recently 
provided data to support the allosteric binding and activation theory between STACs and 
SIRT1. They found that specific hydrophobic motifs in SIRT1 substrates and a single 
amino acid (Glu 230) in SIRT1 protein mediate the structure change during the 
deaceytlation [43]. As a highly hydrophobic amino acid, leucine might also directly 
activate SIRT1 through structural conformation. Indeed, recent evidence demonstrates 
that leucine exerts a direct effect on SIRT1 kinetics, by decreasing 50% of SIRT1 Km for 
NAD+. With the presence of leucine and HMB, lower concentration of resveratrol is 
required for the activation of SIRT1 [44]. Therefore, further experiments using 
fluorophore-free substrates to measure the SIRT1 activity are needed to elucidate the 
exact pathways of leucine binding and activating SIRT1. A second limitation is lack of 
data assessing the cellular acetylation status of LKB1 and PGC-1α, as well as Nampt 
phosphorylation.  
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Part Four 
Conclusions 
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In this dissertation, we have shown that leucine can regulate aerobic metabolism 
in skeletal muscle cells. Leucine-induced mitochondrial biogenesis, due to the activation 
of SIRT1 and AMPK, results in increased mitochondrial content and fatty acid oxidation. 
We demonstrate that both SIRT1 and AMPK are required to mediate leucine action in 
myotubes. Moreover, we have characterized that leucine-promoted secondary activation 
of AMPK in C2C12 myotubes is mediated by SIRT1 using time-course analyses. We 
conclude that nutrients such as leucine can regulate myotubes energy metabolism. With 
the data presented here, we are able to provide evidence to in vivo leucine studies in 
which the activation of SIRT1 and AMPK must be considered. 
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